Kimberly-Clark (KMB) 10-K 18 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 11, 2015	Jun. 30, 2014
Entity Information [Line Items]
Entity Registrant Name	KIMBERLY CLARK CORP
Entity Central Index Key	55785
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		365,468,649
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$41,600,000,000

Consolidated_Income_Statement

Consolidated Income Statement (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Statement [Abstract]
Net Sales	$19,724	[1]	$19,561	[1]	$19,467	[1]
Cost of products sold	13,041		12,952		13,338
Gross Profit	6,683		6,609		6,129
Marketing, research and general expenses	3,709		3,699		3,757
Other (income) and expense, net	453		7	[2]	-5	[2]
Operating Profit	2,521	[2]	2,903	[2]	2,377	[2]
Interest income	18		20		18
Interest expense	-284		-282		-285
Income From Continuing Operations Before Income Taxes and Equity Interests	2,255		2,641		2,110
Provision for income taxes	-856		-828		-660
Income From Continuing Operations Before Equity Interests	1,399		1,813		1,450
Share of net income of equity companies	146		205		177
Income From Continuing Operations	1,545		2,018		1,627
Income from discontinued operations, net of income taxes	50		203		201
Net Income	1,595		2,221		1,828
Net income attributable to noncontrolling interests in continuing operations	-69		-79		-78
Net Income Attributable to Kimberly-Clark Corporation	$1,526		$2,142		$1,750
Basic
Continuing operations (per share)	$3.94		$5.05		$3.94
Discontinued operations (per share)	$0.13		$0.53		$0.51
Net income (per share)	$4.07		$5.58		$4.45
Diluted
Continuing operations (per share)	$3.91		$5.01		$3.91
Discontinued operations (per share)	$0.13		$0.52		$0.51
Net income (per share)	$4.04		$5.53		$4.42
Cash Dividends Declared (per share)	$3.36		$3.24		$2.96
[1]	Net sales in the United States to third parties totaled $8,573, $8,557 and $8,514 in 2014, 2013 and 2012, respectively.
[2]	Segment operating profit excludes other (income) and expense, net and income and expenses not associated with the business segments.

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income	$1,595	$2,221	$1,828
Other Comprehensive Income (Loss), Net of Tax
Unrealized currency translation adjustments	-835	-494	215
Employee postretirement benefits	-275	302	-377
Other	20	17	-16
Total Other Comprehensive Income (Loss), Net of Tax	-1,090	-175	-178
Comprehensive Income	505	2,046	1,650
Comprehensive income attributable to noncontrolling interests	-57	-87	-93
Comprehensive Income Attributable to Kimberly-Clark Corporation	$448	$1,959	$1,557

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$789,000,000	$1,054,000,000
Accounts receivable, net	2,223,000,000	2,545,000,000
Inventories	1,892,000,000	2,233,000,000
Other current assets	655,000,000	718,000,000
Total Current Assets	5,559,000,000	6,550,000,000
Property, Plant and Equipment, Net	7,359,000,000	7,948,000,000
Investments in Equity Companies	257,000,000	382,000,000
Goodwill	1,628,000,000	3,181,000,000
Other Intangible Assets, Net	109,000,000	243,000,000
Other Assets	614,000,000	615,000,000
TOTAL ASSETS	15,526,000,000	18,919,000,000
Current Liabilities
Debt payable within one year	1,326,000,000	375,000,000
Redeemable preferred securities of subsidiary	0	506,000,000
Trade accounts payable	2,616,000,000	2,598,000,000
Accrued expenses	1,974,000,000	2,060,000,000
Dividends payable	310,000,000	309,000,000
Total Current Liabilities	6,226,000,000	5,848,000,000
Long-Term Debt	5,630,000,000	5,386,000,000
Noncurrent Employee Benefits	1,693,000,000	1,312,000,000
Deferred Income Taxes	587,000,000	817,000,000
Other Liabilities	319,000,000	344,000,000
Redeemable Preferred and Common Securities of Subsidiaries	72,000,000	72,000,000
Stockholders' Equity
Preferred stock—no par value—authorized 20.0 million shares, none issued	0	0
Common stock—$1.25 par value—authorized 1.2 billion shares; issued 428.6 million shares at December 31, 2014 and 2013	536,000,000	536,000,000
Additional paid-in capital	632,000,000	594,000,000
Common stock held in treasury, at cost—63.3 million and 47.8 million shares at December 31, 2014 and 2013	-5,597,000,000	-3,746,000,000
Retained earnings	8,470,000,000	9,714,000,000
Accumulated other comprehensive income (loss)	-3,312,000,000	-2,242,000,000
Total Kimberly-Clark Corporation Stockholders' Equity	729,000,000	4,856,000,000
Noncontrolling Interests	270,000,000	284,000,000
Total Stockholders' Equity	999,000,000	5,140,000,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$15,526,000,000	$18,919,000,000

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$0	$0
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$1.25	$1.25
Common stock, shares authorized	1,200,000,000	1,200,000,000
Common stock, shares issued	428,600,000	428,600,000
Common stock held in treasury, shares	63,261,000	47,798,000

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock Issued [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member]
In Millions, except Share data in Thousands, unless otherwise specified								Dividend Declared [Member]
Beginning Balance at Dec. 31, 2011		$536	$440	($2,105)	$8,244	($1,866)	$280
Beginning Balance, treasury stock (in shares) at Dec. 31, 2011	32,937
Beginning Balance (in shares) at Dec. 31, 2011		428,597
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income in stockholders' equity	1,828				1,750
Net income in stockholders' equity							47
Other comprehensive income, net of tax
Unrealized translation	215					195	20
Employee postretirement benefits	-377					-372	-5
Other	-16					-16	0
Stock-based awards exercised or vested			-78	643
Stock-based awards exercised or vested (in shares)				-10,492
Income tax benefits on stock-based compensation	20		43
Shares repurchased (in shares)				16,877
Shares repurchased				-1,333
Recognition of stock-based compensation			67
Dividends declared					-1,163
Distributions to noncontrolling interests							38
Other			9	-1	-8		-2
Ending Balance at Dec. 31, 2012		536	481	-2,796	8,823	-2,059	302
Ending Balance, treasury stock (in shares) at Dec. 31, 2012	39,322
Ending Balance (in shares) at Dec. 31, 2012		428,597
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income in stockholders' equity	2,221				2,142
Net income in stockholders' equity							48
Other comprehensive income, net of tax
Unrealized translation	-494					-499	5
Employee postretirement benefits	302					298	4
Other	17					18	-1
Stock-based awards exercised or vested			-33	264
Stock-based awards exercised or vested (in shares)				-4,108
Income tax benefits on stock-based compensation	35		46
Shares repurchased (in shares)				12,584
Shares repurchased				-1,214
Recognition of stock-based compensation			92
Dividends declared					-1,244
Distributions to noncontrolling interests							39
Other			8	0	-7		-35
Ending Balance at Dec. 31, 2013	5,140	536	594	-3,746	9,714	-2,242	284
Ending Balance, treasury stock (in shares) at Dec. 31, 2013	47,798
Ending Balance (in shares) at Dec. 31, 2013		428,597
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income in stockholders' equity	1,595				1,526
Net income in stockholders' equity							39
Other comprehensive income, net of tax
Unrealized translation	-835					-819	-15
Employee postretirement benefits	-275					-278	3
Other	20					19	1
Stock-based awards exercised or vested			-54	180
Stock-based awards exercised or vested (in shares)				-2,783
Income tax benefits on stock-based compensation	19		32
Shares repurchased (in shares)				18,246
Shares repurchased				-2,031
Recognition of stock-based compensation			52
Dividends declared					-1,256
Distributions to noncontrolling interests								43
Spin-off of health care business					-1,505	9
Other			8	0	-9	-1	1
Ending Balance at Dec. 31, 2014	$999	$536	$632	($5,597)	$8,470	($3,312)	$270
Ending Balance, treasury stock (in shares) at Dec. 31, 2014	63,261
Ending Balance (in shares) at Dec. 31, 2014		428,597

Consolidated_Cash_Flow_Stateme

Consolidated Cash Flow Statement (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Activities
Net income	$1,595	$2,221	$1,828
Depreciation and amortization	862	863	857
Asset impairments	42	45	171
Stock-based compensation	52	92	67
Deferred income taxes	63	151	224
Net (gains) losses on asset dispositions	21	11	35
Equity companies' earnings (in excess of) less than dividends paid	28	-36	-27
(Increase) decrease in operating working capital	-176	-158	119
Postretirement benefits	-102	-158	7
Charge for Venezuelan balance sheet remeasurement	462	36	0
Other	-2	-27	7
Cash Provided by Operations	2,845	3,040	3,288
Investing Activities
Capital spending	-1,039	-953	-1,093
Acquisitions of businesses	0	-32	-5
Proceeds from dispositions of property	38	129	9
Proceeds from sales of investments	127	26	23
Investments in time deposits	-151	-93	-212
Maturities of time deposits	239	94	95
Other	16	-15	-1
Cash Used for Investing	-770	-844	-1,184
Financing Activities
Cash dividends paid	-1,256	-1,223	-1,151
Change in short-term borrowings	721	-287	271
Debt proceeds	1,257	890	315
Debt repayments	-123	-544	-492
Redemption of redeemable preferred securities of subsidiary	-500	0	0
Cash paid on redeemable preferred securities of subsidiaries	-34	-27	-28
Proceeds from exercise of stock options	127	232	565
Acquisitions of common stock for the treasury	-1,939	-1,216	-1,284
Cash transferred to Halyard Health, Inc. related to spin-off	-120	0	0
Other	-26	-10	2
Cash Used for Financing	-1,893	-2,185	-1,802
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-447	-63	40
Increase (Decrease) in Cash and Cash Equivalents	-265	-52	342
Cash and Cash Equivalents - Beginning of Year	1,054	1,106	764
Cash and Cash Equivalents - End of Year	$789	$1,054	$1,106

Accounting_Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies
	Basis of Presentation
	The Consolidated Financial Statements present the accounts of Kimberly-Clark Corporation and all subsidiaries in which it has a controlling financial interest as if they were a single economic entity in conformity with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany transactions and accounts are eliminated in consolidation. The terms "Corporation," "Kimberly-Clark," "we," "our," and "us" refer to Kimberly-Clark Corporation and all subsidiaries in which it has a controlling financial interest. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. Kimberly-Clark’s prior period Consolidated Income Statements and related disclosures have been recast to present the results of the spun-off health care business (see further discussion below) as discontinued operations. Segment results have also been recast to present net sales and operating profit by segment on a continuing operations basis.
	On October 31, 2014, we completed the spin-off of our health care business, creating a stand-alone, publicly traded health care company, Halyard Health, Inc. ("Halyard"), by distributing 100 percent of the outstanding shares of Halyard to holders of our common stock. See Note 2 for more information. The spun-off health care business is presented as discontinued operations on the Consolidated Income Statement for all periods presented. The health care business' balance sheet, other comprehensive income and cash flows are included within our Consolidated Balance Sheet, Consolidated Statement of Stockholders' Equity, Consolidated Statement of Comprehensive Income and Consolidated Cash Flow Statement through October 31, 2014.
	Use of Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Actual results could differ from these estimates, and changes in these estimates are recorded when known. Estimates are used in accounting for, among other things, sales incentives and trade promotion allowances, employee postretirement benefits, and deferred income taxes and potential assessments.
	Cash Equivalents
	Cash equivalents are short-term investments with an original maturity date of three months or less.
	Inventories and Distribution Costs
	Most U.S. inventories are valued at the lower of cost, using the Last-In, First-Out (LIFO) method, or market. The balance of the U.S. inventories and inventories of consolidated operations outside the U.S. are valued at the lower of cost, using either the First-In, First-Out (FIFO) or weighted-average cost methods, or market. Distribution costs are classified as cost of products sold.
	Property and Depreciation
	Property, plant and equipment are stated at cost and are depreciated on the straight-line method. Buildings are depreciated over their estimated useful lives, primarily 40 years. Machinery and equipment are depreciated over their estimated useful lives, primarily ranging from 16 to 20 years. Purchases of computer software, including external costs and certain internal costs (including payroll and payroll-related costs of employees) directly associated with developing significant computer software applications for internal use, are capitalized. Computer software costs are amortized on the straight-line method over the estimated useful life of the software, which generally does not exceed 5 years.
	Estimated useful lives are periodically reviewed and, when warranted, changes are made to them. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss would be indicated when estimated undiscounted future cash flows from the use and eventual disposition of an asset group, which are identifiable and largely independent of the cash flows of other asset groups, are less than the carrying amount of the asset group. Measurement of an impairment loss would be based on the excess of the carrying amount of the asset group over its fair value. Fair value is measured using discounted cash flows or independent appraisals, as appropriate. When property is sold or retired, the cost of the property and the related accumulated depreciation are removed from the Consolidated Balance Sheet and any gain or loss on the transaction is included in income.
	Goodwill and Other Intangible Assets
	Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Goodwill is not amortized, but rather is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. Impairment testing compares the reporting unit carrying amount of goodwill with its fair value. Fair value is estimated based on discounted cash flows. If the reporting unit carrying amount of goodwill exceeds its fair value, an impairment charge would be recorded. For 2014, we have completed the required annual testing of goodwill for impairment for all reporting units using the first day of the third quarter as the measurement date, and have determined that goodwill is not impaired.
	Intangible assets with finite lives are amortized over their estimated useful lives and are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Estimated useful lives range from 2 to 20 years for trademarks, 5 to 15 years for patents and developed technologies, and 5 to 15 years for other intangible assets. An impairment loss would be indicated when estimated undiscounted future cash flows from the use of the asset are less than its carrying amount. An impairment loss would be measured as the difference between the fair value (based on discounted future cash flows) and the carrying amount of the asset.
	Investments in Equity Companies
	Investments in companies which we do not control but over which we have the ability to exercise significant influence and that, in general, are at least 20 percent-owned by us, are stated at cost plus equity in undistributed net income. These investments are evaluated for impairment when warranted. An impairment loss would be recorded whenever a decline in value of an equity investment below its carrying amount is determined to be other than temporary. In judging "other than temporary," we would consider the length of time and extent to which the fair value of the equity company investment has been less than the carrying amount, the near-term and longer-term operating and financial prospects of the equity company, and our longer-term intent of retaining the investment in the equity company.
	Revenue Recognition
	Sales revenue is recognized at the time of product shipment or delivery, depending on when title passes, to unaffiliated customers, and when all of the following have occurred: a firm sales agreement is in place, pricing is fixed or determinable, and collection is reasonably assured. Sales are reported net of returns, consumer and trade promotions, rebates and freight allowed. Taxes imposed by governmental authorities on our revenue-producing activities with customers, such as sales taxes and value-added taxes, are excluded from net sales.
	Sales Incentives and Trade Promotion Allowances
	The cost of promotion activities provided to customers is classified as a reduction in sales revenue. In addition, the estimated redemption value of consumer coupons is recorded at the time the coupons are issued and classified as a reduction in sales revenue. Estimates of trade promotion liabilities for promotional program costs incurred, but unpaid, are generally based on estimates of the quantity of customer sales, timing of promotional activities and forecasted costs for activities within the promotional programs.
	Advertising Expense
	Advertising costs are expensed in the year the related advertisement or campaign is first presented by the media. For interim reporting purposes, advertising expenses are charged to operations as a percentage of sales based on estimated sales and related advertising expense for the full year.
	Research Expense
	Research and development costs are charged to expense as incurred.
	Foreign Currency Translation
	The income statements of foreign operations, other than those in highly inflationary economies, are translated into U.S. dollars at rates of exchange in effect each month. The balance sheets of these operations are translated at period-end exchange rates, and the differences from historical exchange rates are reflected in stockholders' equity as unrealized translation adjustments.
	The income statements and balance sheets of operations in highly inflationary economies are translated into U.S. dollars using both current and historical rates of exchange. We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after-tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to this devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the year ended December 31, 2013.
	During March 2013, the Venezuelan government announced a complementary currency exchange system, SICAD. Participation in SICAD is controlled by the Venezuelan government. SICAD is intended to function as an auction system, allowing entities in specific sectors to bid for U.S. dollars to be used for specified import transactions. In February 2014, the president of Venezuela announced that another floating rate exchange system (referred to as SICAD II) would be initiated. Initial exchanges under SICAD II began on March 24, 2014.
	We have historically measured results in Venezuela at the rate in which we transact our business. We have qualified for access to the official exchange rate because we manufacture and sell price-controlled products. Since March 2013, exchange transactions have taken place through letters of credit which resulted in an effective exchange rate of 6.3 bolivars per U.S. dollar and through approved transactions using the regulated currency exchange system, which were also at a 6.3 exchange rate. To date, we have not been invited to participate in SICAD, and we did not seek exchange at SICAD II because we qualify for the more favorable official 6.3 rate and have chosen to pursue exchange at that rate.
	Through December 31, 2014, we continued to manufacture and sell products in Venezuela as well as import raw materials and finished goods under approved foreign exchange transactions. However, recent government approvals for imports under letters of credit have not been at a level sufficient to sustain all of our manufacturing capabilities in Venezuela. During December 2014, the volume of exchange transactions approved at the 6.3 exchange rate decreased significantly, and we experienced some level of production curtailment during the fourth quarter of 2014. We continued to measure results at the 6.3 rate through December 2014, however, we are uncertain whether approved exchange transactions at the 6.3 exchange rate will recover to previous levels. Given the level of uncertainty and lack of liquidity in Venezuela, in part due to recent declines in the price of oil, we remeasured our local currency-denominated balance sheet as of December 31, 2014 at the year end floating SICAD II exchange rate of 50 bolivars per U.S. dollar as we believe this was the most accessible rate available in the absence of exchange at 6.3 bolivars per U.S. dollar. This remeasurement resulted in a non-deductible charge of $462 in the Consolidated Income Statement for the year ended December 31, 2014, with $41 recorded in cost of products sold and $421 recorded in other (income) and expense, net.
	At December 31, 2014, K-C Venezuela had a bolivar-denominated net monetary asset position (primarily cash) of $59 and our net investment in K-C Venezuela was $152, both valued at 50 bolivars per U.S. dollar. Net sales of K-C Venezuela represented approximately 3 percent of consolidated net sales for the year ended December 31, 2014 and approximately 2 percent of consolidated net sales for the years ended December 31, 2013 and 2012.
	While we continue to seek approval for additional imports at the official rate, unless we are able to obtain further approvals for imports through approved letters of credit or through the official government exchange system, we may be forced to curtail some or all of our local manufacturing in the future until such approvals to import additional raw materials are forthcoming. In January 2015, we measured results in Venezuela at the floating SICAD II exchange rate. In mid-February 2015, the government of Venezuela announced changes to their three-tiered currency exchange system. We are evaluating the implications of these changes to assess the impact on our results and reporting for our operations in that country.
	Derivative Instruments and Hedging
	Our policies allow the use of derivatives for risk management purposes and prohibit their use for speculation. Our policies also prohibit the use of any leveraged derivative instrument. Consistent with our policies, foreign currency derivative instruments, interest rate swaps and locks, and the majority of commodity hedging contracts are entered into with major financial institutions. At inception we formally designate certain derivatives as cash flow, fair value or net investment hedges and establish how the effectiveness of these hedges will be assessed and measured. This process links the derivatives to the transactions or financial balances they are hedging. Changes in the fair value of derivatives not designated as hedging instruments are recorded in earnings as they occur. All derivative instruments are recorded as assets or liabilities on the balance sheet at fair value. Changes in the fair value of derivatives are either recorded in the income statement or other comprehensive income, as appropriate. The gain or loss on derivatives designated as fair value hedges and the offsetting loss or gain on the hedged item attributable to the hedged risk are included in income in the period that changes in fair value occur. The effective portion of the gain or loss on derivatives designated as cash flow hedges is included in other comprehensive income in the period that changes in fair value occur, and is reclassified to income in the same period that the hedged item affects income. The gain or loss on derivatives designated as hedges of investments in foreign subsidiaries is recognized in other comprehensive income to offset the change in value of the net investments being hedged. Any ineffective portion of cash flow hedges and net investment hedges is immediately recognized in income. Certain foreign-currency derivative instruments not designated as hedging instruments have been entered into to manage a portion of our foreign currency transactional exposures. The gain or loss on these derivatives is included in income in the period that changes in their fair values occur. See Note 15 for disclosures about derivative instruments and hedging activities.
	New Accounting Standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance.  The standard is effective for public entities for annual and interim periods beginning after December 15, 2016.  Early adoption is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The effects of this standard on our financial position, results of operations and cash flows are not yet known.

Spinoff_of_Health_Care_Busines

Spinoff of Health Care Business and Related Costs (Notes) (Health Care Spin-off [Member])	12 Months Ended
	Dec. 31, 2014
Health Care Spin-off [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Spin-Off of Health Care Business and Related Costs [Text Block]	Spin-Off of Health Care Business and Related Costs
	On October 31, 2014, we completed the spin-off of our health care business, and each of our shareholders of record as of the close of business on October 23, 2014 (the "Record Date") received one share of Halyard common stock for every 8 shares of our common stock held as of the Record Date. The distribution was structured to be tax free to our U.S. shareholders for U.S. federal income tax purposes. After the distribution, we do not beneficially own any shares of Halyard common stock.
	Summary results of operations for the spun-off health care business included in net income from discontinued operations, net of income taxes, were as follows:
		Year Ended December 31
		2014			2013			2012
	Net sales	$	1,320		$	1,591		$	1,596
	Income before income taxes	130			304			310
	Provision for income taxes	(80		)	(101		)	(109		)
	Net income	50			203			201
	The results of the health care discontinued operations exclude certain corporate costs which were allocated to the health care segment historically and we expect to continue to incur these costs after the spin-off. These include costs related to supply chain, finance, legal, information technology, human resources, compliance, shared services, insurance, employee benefits and incentives, and stock-based compensation. On a pre-tax basis, through the date of the spin-off, these costs were $70 for the ten months ended October 31, 2014, and $85 in each of the years ended December 31, 2013 and 2012.
	To evaluate, plan and execute the spin-off, we incurred $157 of pre-tax charges ($138 after tax) in transaction and related costs, including the exit of one of Halyard's health care glove manufacturing facilities in Thailand and outsourcing of the related production. These charges and the related tax impact are recorded in Income from discontinued operations, net of income taxes.
	In connection with the spin-off, we transferred the following assets and liabilities to Halyard:
	Assets
	Cash	$	120
	Accounts receivable, net	37
	Inventories	289
	Property, plant and equipment, net	271
	Goodwill	1,429
	Other intangible assets	114
	Other assets	66
	Total Assets	$	2,326
	Liabilities
	Accrued expenses	$	127
	Debt	636
	Deferred income taxes	60
	Other liabilities	7
	Total Liabilities	$	830
	Net Assets Transferred in the Spin-Off	$	1,496
	In order to implement the spin-off, we entered into certain agreements with Halyard to effect our legal and structural separation; govern the relationship between us; and allocate various assets, liabilities and obligations between us, including, among other things, employee benefits, intellectual property and tax-related assets and liabilities. We also entered into a transition services agreement with Halyard, whereby we will provide certain administrative and other services for a limited time, a tax matters agreement, an employee matters agreement, intellectual property agreements, manufacturing and supply agreements, distribution agreements and non-competition agreements.

2014_Organization_Restructurin

2014 Organization Restructuring 2014 Organization Restructuring (2014 Organization Restructuring [Member])	12 Months Ended
	Dec. 31, 2014
2014 Organization Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
2014 Organization Restructuring	2014 Organization Restructuring
	In October 2014, we initiated a restructuring plan in order to improve organization efficiency and offset the impact of stranded overhead costs resulting from the spin-off of our health care business. The restructuring is intended to improve our underlying profitability and increase our flexibility to invest in targeted growth initiatives, brand building and other capabilities critical to delivering future growth.
	The restructuring is expected to be completed by the end of 2016, with total costs, primarily severance, anticipated to be $130 to $160 after tax ($190 to $230 pre-tax). Cash costs are projected to be approximately 80 percent of the total charges. Workforce reductions are expected to be in the range of 1,100 to 1,300 and primarily impact salaried employees. The restructuring is expected to impact all of our business segments and our organizations in all major geographies.
	Charges in the fourth quarter of 2014 were $133, recorded in the following income statement line items:
		2014
	Cost of products sold	$	40
	Marketing, research and general expenses	93
	Provision for income taxes	(38		)
	Net charges	$	95
	Cash payments in the fourth quarter of 2014 related to the restructuring were not material. On a geographic basis, $47 of the charges were recorded in North America, $28 in Europe, and $58 in our international operations in Asia, Latin America, the Middle East, Eastern Europe and Africa.

European_Strategic_Changes

European Strategic Changes (European Strategic Changes [Member])	12 Months Ended
	Dec. 31, 2014
European Strategic Changes [Member]
Restructuring Cost and Reserve
European Strategic Changes	European Strategic Changes
	In 2012, we approved strategic changes related to our Western and Central European consumer and professional businesses to focus our resources and investments on stronger market positions and growth opportunities. We exited the diaper category in that region, with the exception of the Italian market, and divested or exited some lower-margin businesses, mostly in consumer tissue, in certain markets. The changes primarily affected our consumer businesses, with a modest impact on K-C Professional ("KCP"). The restructuring actions commenced in 2012 and were completed by December 31, 2014.
	Restructuring actions related to the strategic changes involved the sale or closure of five of our European manufacturing facilities and streamlining our administrative organization. The following charges were incurred in connection with the European strategic changes:
		Year Ended December 31
		2014			2013			2012
	Asset impairments and other asset-related charges	$	2		$	53		$	165
	Charges for workforce reductions	(5		)	10			77
	Benefit from pension curtailment	—			(31		)	—
	Other exit costs	14			22			8
	Cost of products sold	11			54			250
	Charges for workforce reductions and other exit costs included in marketing, research and general expenses and other (income) and expense, net	22			27			49
	Provision for income taxes	(3		)	(15		)	(57		)
	Net charges	$	30		$	66		$	242
	The measurement of the charges for asset impairments was based on the excess of the carrying value of the impacted asset groups over their fair values.  These fair values were measured using discounted cash flows expected over the limited time the assets would remain in use, and as a result, the assets were essentially written off. The use of the discounted cash flows represents a level 3 measure under the fair value hierarchy.
	Cash payments of $41, $156 and $4 were made during 2014, 2013 and 2012, respectively, related to the restructuring. See Note 18 for charges by segment.

Pulp_And_Tissue_Restructuring

Pulp And Tissue Restructuring (Pulp And Tissue Restructuring [Member])	12 Months Ended
	Dec. 31, 2014
Pulp And Tissue Restructuring [Member]
Restructuring Cost and Reserve
Pulp and Tissue Restructuring	Pulp and Tissue Restructuring Actions
	In 2011 and 2012, we executed pulp and tissue restructuring actions in order to exit our remaining integrated pulp manufacturing operations and improve the underlying profitability and return on invested capital of our consumer tissue and KCP businesses. These actions involved the streamlining, sale or closure of seven of our manufacturing facilities around the world. In conjunction with these actions, we exited certain non-strategic products, primarily non-branded offerings, and transferred some production to lower-cost facilities in order to improve overall profitability and returns. The actions were substantially complete at December 31, 2012. The restructuring resulted in cumulative pre-tax charges of $550 ($375 after tax). During 2012, charges of $135 were recorded primarily in cost of products sold for the restructuring actions, and a related benefit of $49 was recorded in provision for income taxes. See Note 18 for charges by segment.

Fair_Value_Information

Fair Value Information	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Information	Fair Value Information
	The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
	Level 1—Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
	Level 2—Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
	Level 3—Prices or valuations that require inputs that are significant to the valuation and are unobservable.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	During 2014 and 2013, there were no significant transfers among level 1, 2 or 3 fair value determinations.
	Company-owned life insurance ("COLI") assets and derivative assets and liabilities are measured on a recurring basis at fair value. COLI assets were $58 and $55 at December 31, 2014 and 2013, respectively. The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in other assets. The fair value of the COLI policies is considered a level 2 measurement and is derived from investments in a mix of money market, fixed income and equity funds managed by unrelated fund managers. At December 31, 2014 and 2013, derivative assets were $54 and $62, respectively, and derivative liabilities were $116 and $49, respectively. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves and NYMEX price quotations, respectively. The fair value of hedging instruments used to manage foreign currency risk is based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Measurement of our derivative assets and liabilities is considered a level 2 measurement. Additional information on our classification and use of derivative instruments is contained in Note 15.
	The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
		Fair Value	Carrying		Estimated		Carrying		Estimated
		Hierarchy	Amount		Fair		Amount		Fair
		Level			Value				Value
			December 31, 2014				December 31, 2013
	Assets
	Cash and cash equivalents(a)	1	$	789	$	789	$	1,054	$	1,054
	Time deposits(b)	1	130		130		222		222
	Liabilities and redeemable securities of subsidiaries
	Short-term debt(c)	2	777		777		63		63
	Long-term debt(d)	2	6,179		6,963		5,698		6,721
	Redeemable securities of subsidiaries(e)	3	72		72		578		598
	(a)	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
	(b)	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
	(c)	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
	(d)	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
	(e)	The redeemable securities of subsidiaries are not traded in active markets. For certain instruments, fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest or dividend payment dates. Additionally, the fair value of the remaining redeemable securities was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Acquisitions_and_Intangible_As

Acquisitions and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Acquisitions and Intangible Assets	Acquisitions and Intangible Assets
	The changes in the carrying amount of goodwill by business segment are as follows:
		Personal			Consumer			K-C			Health Care			Total
		Care			Tissue			Professional			Business
	Balance at December 31, 2012	$	764		$	695		$	442		$	1,436		$	3,337
	Acquisitions	6			—			—			3			9
	Currency and other	(86		)	(54		)	(18		)	(7		)	(165		)
	Balance at December 31, 2013	684			641			424			1,432			3,181
	Currency and other	(59		)	(47		)	(15		)	(3		)	(124		)
	Spin-off of health care business	—			—			—			(1,429		)	(1,429		)
	Balance at December 31, 2014	$	625		$	594		$	409		$	—		$	1,628
	Intangible assets subject to amortization consist of the following at December 31:
		2014						2013
		Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Amount						Amount
	Trademarks	$	117		$	79		$	252		$	163
	Patents and developed technologies	49			9			201			85
	Other	64			33			93			62
	Total	$	230		$	121		$	546		$	310

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	Debt
	Long-term debt is composed of the following:
		Weighted-	Maturities	December 31
		Average
		Interest
		Rate		2014		2013
	Notes and debentures	4.70%	2015 - 2043	$	5,656	$	5,163
	Dealer remarketable securities	4.30%	2015 - 2016	200		200
	Industrial development revenue bonds	0.20%	2015 - 2034	261		261
	Bank loans and other financings in various currencies	5.80%	2015 - 2025	62		74
	Total long-term debt			6,179		5,698
	Less current portion			549		312
	Long-term portion			$	5,630	$	5,386
	Scheduled maturities of long-term debt for the next five years are $549 in 2015, $607 in 2016, $963 in 2017, $905 in 2018 and $311 in 2019.
	On October 17, 2014, we issued debt of $640 aggregate principal amount that was transferred to Halyard as part of the spin-off.
	On May 22, 2014, we issued $300 aggregate principal amount of floating rate notes due May 19, 2016 and $300 aggregate principal amount of 1.9% notes due May 22, 2019. Proceeds from the offering were used for general corporate purposes and repurchases of common stock.
	In 2013, we issued $250 aggregate principal amount of floating rate notes due May 15, 2016, $350 aggregate principal amount of 2.4% notes due June 1, 2023, and $250 aggregate principal amount of 3.7% notes due June 1, 2043. Proceeds from the offering were used to repay our $500 aggregate principal amount of 5.0% notes due August 15, 2013, to fund investment in our business and for general corporate purposes.
	In 2012, we issued $300 aggregate principal amount of 2.4% notes due March 1, 2022.  Proceeds from the offering were used for general corporate purposes and repayment of debt.
	In 2006, we issued $200 of dealer remarketable securities that have a final maturity in 2016. The remarketing provisions of these debt instruments require that each year the securities either be remarketed by the dealer or repaid. In both 2014 and 2013, the dealer exercised its option to remarket the securities for another year, and remarketed the securities to third parties.
	In June 2014, we entered into a $2.0 billion revolving credit facility which expires in 2019.  This facility, currently unused, replaced a similar facility for $1.5 billion, supports our commercial paper program, and would provide liquidity in the event our access to the commercial paper markets is unavailable for any reason.

Redeemable_Preferred_and_Commo

Redeemable Preferred and Common Securities of Subsidiaries	12 Months Ended
	Dec. 31, 2014
Temporary Equity Disclosure [Abstract]
Redeemable Securities of Subsidiaries	Redeemable Securities of Subsidiaries
	In February 2001, we, together with a non-affiliated third party entity, (the "Third Party"), formed a Luxembourg-based financing subsidiary. Prior to December 2014, the Third Party had an investment in certain redeemable preferred securities of the subsidiary. Kimberly-Clark holds investments in certain preferred securities and all of the common securities of the subsidiary. Approximately 98 percent of the total cash contributed to the subsidiary was loaned to Kimberly-Clark. We are the primary beneficiary of the subsidiary and, accordingly, consolidated the subsidiary in our Consolidated Financial Statements.
	In December 2013, the subsidiary elected to redeem the preferred securities held by the Third Party in December 2014, and as a result, the $500 redemption value of the subsidiary’s preferred securities held by the Third Party was included in current liabilities as of December 31, 2013 in our Consolidated Balance Sheet. These preferred securities were redeemed in December 2014, and accordingly, the subsidiary became wholly-owned by Kimberly-Clark.
	The preferred and common securities of the subsidiary held by Kimberly-Clark and the intercompany loans have been eliminated in our Consolidated Financial Statements. The return on the preferred securities previously held by the Third Party was $26, $27 and $27 in 2014, 2013 and 2012, respectively, which is included in net income attributable to noncontrolling interests in our Consolidated Income Statement.
	In addition, our subsidiary in Central America has outstanding redeemable securities that are held by a noncontrolling interest, which were exchanged from common to preferred securities in December 2014, and another noncontrolling interest holds certain redeemable preferred securities issued by one of our subsidiaries in North America.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Share-based Compensation [Abstract]
Stock-Based Compensation	Stock-Based Compensation
	We have a stock-based Equity Participation Plan and an Outside Directors' Compensation Plan (the "Plans"), under which we can grant stock options, restricted shares and restricted share units to employees and outside directors. As of December 31, 2014, the number of shares of common stock available for grants under the Plans aggregated 22 million shares.
	Stock options are granted at an exercise price equal to the fair market value of our common stock on the date of grant, and they have a term of 10 years. Stock options are subject to graded vesting whereby options vest 30 percent at the end of each of the first two 12-month periods following the grant and 40 percent at the end of the third 12-month period.
	Restricted shares, time-vested restricted share units and performance-based restricted share units granted to employees are valued at the closing market price of our common stock on the grant date and vest generally at the end of three years. The number of performance-based share units that ultimately vest ranges from zero to 200 percent of the number granted, based on performance tied to return on invested capital ("ROIC") and net sales during the three-year performance period. ROIC and net sales targets are set at the beginning of the performance period. Restricted share units granted to outside directors are valued at the closing market price of our common stock on the grant date and vest when they are granted. The restricted period begins on the date of grant and expires on the date the outside director retires from or otherwise terminates service on our Board.
	At the time stock options are exercised or restricted shares and restricted share units become payable, common stock is issued from our accumulated treasury shares. Dividend equivalents are credited on restricted share units on the same date and at the same rate as dividends are paid on Kimberly-Clark's common stock. These dividend equivalents, net of estimated forfeitures, are charged to retained earnings.
	In connection with the spin-off of our health care business, under the provisions of our existing Plans, employee stock options, time-vested restricted share units and performance-based restricted share units were adjusted as follows:
	•	The number of stock options was increased and the exercise price was decreased to maintain the fair value of outstanding options immediately before and after the spin-off.
	•	The time-vested restricted share units and performance-based restricted share units were credited with a reinvested dividend equivalent equal to the value of the spin-off stock dividend to maintain the value of these awards immediately before and after the spin-off.
	As a result, we did not record any incremental compensation expenses related to the conversion of these awards. These awards continue to vest over the original vesting period.
	Stock-based compensation costs of $52, $92 and $67 and related deferred income tax benefits of $19, $35 and $20 were recognized for 2014, 2013 and 2012, respectively.
	The fair value of stock option awards was determined using a Black-Scholes-Merton option-pricing model utilizing a range of assumptions related to dividend yield, volatility, risk-free interest rate, and employee exercise behavior. Dividend yield is based on historical experience and expected future dividend actions. Expected volatility is based on a blend of historical volatility and implied volatility from traded options on Kimberly-Clark's common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. We estimate forfeitures based on historical data.
	The weighted-average fair value of options granted was estimated at $7.89, $7.15 and $3.25, in 2014, 2013 and 2012, respectively, per option on the date of grant based on the following assumptions:
		Year Ended December 31
		2014		2013		2012
	Dividend yield	3.5	%	3.7	%	4.5	%
	Volatility	13.41	%	15.4	%	12.86	%
	Risk-free interest rate	1.73	%	0.87	%	1.08	%
	Expected life—years	5		5.1		5.8
	Total remaining unrecognized compensation costs and amortization period are as follows:
		December 31, 2014			Weighted-
					Average
					Service
					Years
	Nonvested stock options	$	8		1
	Restricted shares and time-vested restricted share units	5			0.5
	Nonvested performance-based restricted share units	44			1.2
	Excess tax benefits, resulting from tax deductions in excess of the compensation cost recognized, aggregating $37, $50 and $50 were classified as other cash inflows under Financing Activities in the Consolidated Cash Flow Statement for the years ended December 31, 2014, 2013 and 2012, respectively.
	A summary of stock-based compensation is presented below:
	Stock Options	Shares		Weighted-			Weighted-		Aggregate
		(in thousands)		Average			Average		Intrinsic
				Exercise			Remaining		Value
				Price			Contractual
							Term
	Outstanding at January 1, 2014	7,223		$	75.77
	Granted	1,798		112.26
	Exercised	(1,860	)	68.02
	Forfeited or expired	(506	)	97.57
	Conversion for spin-off of health care business	306		82.26
	Outstanding at December 31, 2014	6,961		82.32			6.51		$	231
	Exercisable at December 31, 2014	3,846		68.26			4.76		$	182
	The total intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $79, $138 and $161, respectively.
		Time-Vested					Performance-Based
		Restricted Share					Restricted Share
		Units					Units
	Other Stock-Based Awards	Shares		Weighted-			Shares			Weighted-
		(in thousands)		Average			(in thousands)			Average
				Grant-Date						Grant-Date
				Fair Value						Fair Value
	Nonvested at January 1, 2014	257		$	81.38		2,083			$	79.98
	Granted	73		100.95			842			111.77
	Vested	(70	)	81.97			(894	)		65.02
	Forfeited	(38	)	84.01			(301	)		94.73
	Dividend equivalent for spin-off of health care business	22		78.04			79			95.8
	Nonvested at December 31, 2014	244		86.34			1,809			96.35
	The total fair value of restricted share units that were distributed to participants during 2014, 2013 and 2012 was $102, $45 and $101, respectively.

Employee_Postretirement_Benefi

Employee Postretirement Benefits	12 Months Ended
	Dec. 31, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Employee Postretirement Benefits	Employee Postretirement Benefits
	Substantially all regular employees in North America and the United Kingdom are covered by defined benefit pension plans (the "Principal Plans") and/or defined contribution retirement plans. Certain other subsidiaries have defined benefit pension plans or, in certain countries, termination pay plans covering substantially all regular employees. The funding policy for our qualified defined benefit pension plans is to contribute assets at least equal in amount to regulatory minimum requirements. Nonqualified U.S. plans providing pension benefits in excess of limitations imposed by the U.S. income tax code are not funded.
	Substantially all U.S. retirees and employees have access to our unfunded healthcare and life insurance benefit plans. The annual increase in the consolidated weighted-average healthcare cost trend rate is expected to be 6.3 percent in 2015 and to decline to 5.1 percent in 2023 and thereafter. Assumed healthcare cost trend rates affect the amounts reported for postretirement healthcare benefit plans. A one-percentage-point change in assumed healthcare trend rates would not have a significant effect on our financial results.
	Summarized financial information about postretirement plans, excluding defined contribution retirement plans, is presented below:
		Pension Benefits								Other Benefits
		Year Ended December 31
		2014				2013				2014			2013
	Change in Benefit Obligation
	Benefit obligation at beginning of year	$	6,164			$	6,590			$	761		$	824
	Service cost	46				53				13			17
	Interest cost	279				257				35			32
	Actuarial loss (gain)	986				(422		)		39			(60		)
	Currency and other	(207		)		47				(4		)	—
	Benefit payments from plans	(356		)		(343		)		—			—
	Direct benefit payments	(10		)		(13		)		(56		)	(52		)
	Curtailments and settlements	(42		)		(5		)		—			—
	Benefit obligation at end of year	6,860				6,164				788			761
	Change in Plan Assets
	Fair value of plan assets at beginning of year	5,567				5,375				—			—
	Actual return on plan assets	694				268				—			—
	Employer contributions	185				220				—			—
	Currency and other	(142		)		47				—			—
	Benefit payments	(356		)		(343		)		—			—
	Settlements	(34		)		—				—			—
	Fair value of plan assets at end of year	5,914				5,567				—			—
	Funded Status	$	(946	)		$	(597	)		$	(788	)	$	(761	)
	Amounts Recognized in the Balance Sheet
	Noncurrent asset—prepaid benefit cost	$	6			$	9			$	—		$	—
	Current liability—accrued benefit cost	(13		)		(12		)		(51		)	(56		)
	Noncurrent liability—accrued benefit cost	(939		)		(594		)		(737		)	(705		)
	Net amount recognized	$	(946	)		$	(597	)		$	(788	)	$	(761	)
	Information for the Principal Plans and All Other Pension Plans
		Principal Plans								All Other							Total
										Pension Plans
		Year Ended December 31
		2014				2013				2014			2013				2014				2013
	Projected benefit obligation (“PBO”)	$	6,312			$	5,640			$	548		$	524			$	6,860			$	6,164
	Accumulated benefit obligation (“ABO”)	6,221				5,555				475			439				6,696				5,994
	Fair value of plan assets	5,559				5,205				355			362				5,914				5,567
	The PBO and fair value of plan assets for the Principal Plans include $4,432 and $3,757, respectively, related to the U.S. qualified and nonqualified pension plans as of December 31, 2014. The PBO and fair value of plan assets for the Principal Plans include $3,866 and $3,565, respectively, related to the U.S. qualified and nonqualified pension plans as of December 31, 2013.
	Information for Pension Plans with an ABO in Excess of Plan Assets
		December 31
		2014				2013
	PBO	$	4,983			$	5,722
	ABO	4,908				5,622
	Fair value of plan assets	4,111				5,163
	Components of Net Periodic Benefit Cost
		Pension Benefits											Other Benefits
		Year Ended December 31
		2014				2013				2012			2014				2013				2012
	Service cost	$	46			$	53			$	45		$	13			$	17			$	15
	Interest cost	279				257				279			35				32				36
	Expected return on plan assets(a)	(332		)		(331		)		(329		)	—				—				—
	Recognized net actuarial loss	100				120				111			—				3				1
	Curtailments and settlements	20				(31		)		20			—				—				—
	Other	(3		)		1				(4		)	(1		)		(2		)		(1		)
	Net periodic benefit cost	$	110			$	69			$	122		$	47			$	50			$	51
	(a)	The expected return on plan assets is determined by multiplying the fair value of plan assets at the remeasurement date, typically the prior year-end adjusted for estimated current year cash benefit payments and contributions, by the expected long-term rate of return.
	Weighted-Average Assumptions Used to Determine Net Cost for Years Ended December 31
		Pension Benefits											Other Benefits
		Projected 2015			2014			2013			2012		2014			2013			2012
	Discount rate	3.83	%		4.66	%		4.04	%		4.87	%	4.97	%		3.97	%		4.7	%
	Expected long-term return on plan assets	5.21	%		5.98	%		6.26	%		6.49	%	—			—			—
	Rate of compensation increase	2.63	%		2.67	%		2.73	%		2.91	%	—			—			—
Weighted-Average Assumptions Used to Determine Benefit Obligations at December 31
	Pension Benefits						Other Benefits
	2014			2013			2014			2013
Discount rate	3.83	%		4.66	%		4.28	%		4.97	%
Rate of compensation increase	2.63	%		2.67	%		—			—
Investment Strategies for the Principal Plans
Strategic asset allocation decisions are made considering several risk factors, including plan participants' retirement benefit security, the estimated payments of the associated liabilities, the plan funded status, and Kimberly-Clark's financial condition. The resulting strategic asset allocation is a diversified blend of equity and fixed income investments. Equity investments are typically diversified across geographies and market capitalization. Fixed income investments are diversified across multiple sectors including government issues and corporate debt instruments with a portfolio duration that is consistent with the estimated payment of the associated liability. Actual asset allocation is regularly reviewed and periodically rebalanced to the strategic allocation when considered appropriate. Our 2015 target plan asset allocation for the Principal Plans is 75 percent fixed income securities and 25 percent equity securities.
The expected long-term rate of return is evaluated on an annual basis. In setting this assumption, we consider a number of factors including projected future returns by asset class relative to the current asset allocation. The weighted-average expected long-term rate of return on pension fund assets used to calculate pension expense for the Principal Plans was 6.16 percent in 2014 compared with 6.43 percent in 2013 and will be 5.35 percent in 2015.
Set forth below are the pension plan assets of the Principal Plans measured at fair value, by level in the fair-value hierarchy:
	Fair Value Measurements at December 31, 2014
	Total				Quoted Prices				Significant			Significant Unobservable Inputs (Level 3)
					in Active				Observable
					Markets for				Inputs
					Identical Assets				(Level 2)
					(Level 1)
Cash and Cash Equivalents
Held directly	$	28			$	28			$	—		$	—
Held through mutual and pooled funds	175				9				166			—
Fixed Income
Held directly
U.S. government and municipals	252				71				181			—
U.S. corporate debt	2,167				—				2,167			—
U.S. securitized fixed income	6				—				6			—
Held through mutual and pooled funds
U.S. corporate debt	149				—				149			—
International bonds	1,438				—				1,438			—
Multi-sector	1				1				—			—
Equity
Held directly
U.S. equity	18				18				—			—
Held through mutual and pooled funds
U.S. equity	4				4				—			—
Non-U.S. equity	106				1				105			—
Global equity	1,186				—				1,186			—
Other	29				29				—			—
Total Plan Assets	$	5,559			$	161			$	5,398		$	—
For the U.S. pension plan, equity option strategies are used when appropriate to reduce the volatility of returns on equity investments.  As of December 31, 2014, the U.S. pension plan had equity options in place with a total notional value of approximately $950, and the fair value of the aggregate options was an asset position of $29.  In addition, Treasury futures contracts are used when appropriate to manage duration targets, and equity futures contracts are used to manage the plan’s investment allocation.  As of December 31, 2014, the U.S. plan had Treasury futures contracts in place with a total notional value of approximately $510 and an insignificant fair value. There were no equity futures contracts in place at December 31, 2014. The U.S. plan had Treasury and equity futures contracts with a total notional value of approximately $320 at December 31, 2013 with an insignificant fair value.
	Fair Value Measurements at December 31, 2013
	Total				Quoted Prices				Significant			Significant Unobservable Inputs (Level 3)
					in Active				Observable
					Markets for				Inputs
					Identical Assets				(Level 2)
					(Level 1)
Cash and Cash Equivalents
Held directly	$	33			$	33			$	—		$	—
Held through mutual and pooled funds	173				34				139			—
Fixed Income
Held directly
U.S. government and municipals	211				71				140			—
U.S. corporate debt	1,654				—				1,654			—
U.S. securitized fixed income	8				—				8			—
Held through mutual and pooled funds
U.S. corporate debt	186				—				186			—
International bonds	1,089				—				1,089			—
Multi-sector	2				2				—			—
Equity
Held directly
U.S. equity	1				1				—			—
Held through mutual and pooled funds
U.S. equity	4				4				—			—
Non-U.S. equity	123				1				122			—
Global equity	1,691				—				1,691			—
Other	30				—				—			30
Total Plan Assets	$	5,205			$	146			$	5,029		$	30
During 2014 and 2013, the plan assets did not include a significant amount of Kimberly-Clark common stock.
Inputs and valuation techniques used to measure the fair value of plan assets vary according to the type of security being valued. Substantially all of the equity securities held directly by the plans are actively traded and fair values are determined based on quoted market prices. Fair values of U.S. Treasury securities are determined based on trading activity in the marketplace.
Fair values of U.S. corporate debt, U.S. securitized fixed income and international bonds are typically determined by reference to the values of similar securities traded in the marketplace and current interest rate levels. Multiple pricing services are typically employed to assist in determining these valuations.
Fair values of equity securities and fixed income securities held through units of pooled funds are based on net asset value of the units of the pooled fund determined by the fund manager. Pooled funds are similar in nature to retail mutual funds, but are typically more efficient for institutional investors. The fair value of pooled funds is determined by the value of the underlying assets held by the fund and the units outstanding. The value of the pooled fund is not directly observable, but is based on observable inputs.
Equity securities held directly by the pension trusts and those held through units in pooled funds are monitored as to issuer and industry. Except for U.S. Treasuries, concentrations of fixed income securities are similarly monitored for concentrations by issuer and industry. As of December 31, 2014, there were no significant concentrations of equity or debt securities in any single issuer or industry.
The fair value of other plan assets was determined based on an evaluation of various factors. No other level 3 transfers (in or out) were made in 2014 and 2013.
We expect to contribute up to $100 to our defined benefit pension plans in 2015. Over the next ten years, we expect that the following gross benefit payments will occur:
	Pension Benefits				Other Benefits
2015	$	430			$	52
2016	432				53
2017	438				55
2018	440				57
2019	439				58
2020-2024	2,181				309
Defined Contribution Pension Plans
Our 401(k) profit sharing plan and supplemental plan provide for a matching contribution of a U.S. employee's contributions and accruals, subject to predetermined limits, as well as a discretionary profit sharing contribution, in which contributions will be based on our profit performance. We also have defined contribution pension plans for certain employees outside the U.S.
Costs charged to expense for our defined contribution pension plans were as follows:
	2014				2013				2012
U.S.	$	87			$	90			$	82
Outside the U.S.	34				27				26
Total	$	121			$	117			$	108

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	Accumulated Other Comprehensive Income
	The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:
			Unrealized Translation				Defined Benefit Pension Plans				Other Postretirement Benefit Plans				Cash Flow Hedges and Other
	Balance as of December 31, 2012		$	(26	)		$	(1,928	)		$	(53	)		$	(52	)
	Other comprehensive income (loss) before reclassifications		(499		)		218				36				24
	(Income) loss reclassified from AOCI		—				42			(a)	2			(a)	(6		)
	Net current period other comprehensive income (loss)		(499		)		260				38				18
	Balance as of December 31, 2013		(525		)		(1,668		)		(15		)		(34		)
	Other comprehensive income (loss) before reclassifications		(819		)		(313		)		(23		)		29
	(Income) loss reclassified from AOCI		—				57			(a)	1			(a)	(11		)
	Net current period other comprehensive income (loss)		(819		)		(256		)		(22		)		18
	Spin-off of health care business		9				—				—				—
	Balance as of December 31, 2014		$	(1,335	)		$	(1,924	)		$	(37	)		$	(16	)
	(a)	Included in computation of net periodic pension and postretirement benefits costs (see Note 11)
	Included in the defined benefit pension plans and other postretirement benefit plans balances as of December 31, 2014 is $2,016 and $54 of unrecognized net actuarial loss and unrecognized net prior service credit, respectively, of which $116 and $10 pre-tax, respectively, are expected to be recognized as a component of net periodic benefit cost in 2015.
	The changes in the components of AOCI attributable to Kimberly-Clark, including the tax effect, are as follows:
		Year Ended December 31
		2014				2013				2012
	Unrealized translation	$	(826	)		$	(495	)		$	204
	Tax effect	7				(4		)		(9		)
		(819		)		(499		)		195
	Defined benefit pension plans
	Unrecognized net actuarial loss and transition amount
	Funded status recognition	(624		)		356				(588		)
	Amortization included in net periodic benefit cost	100				120				90
	Currency and other	69				(8		)		(20		)
		(455		)		468				(518		)
	Unrecognized prior service cost/credit
	Funded status recognition	42				—				—
	Amortization included in net periodic benefit cost	(7		)		(31		)		—
	Currency and other	(3		)		(1		)		3
		32				(32		)		3
	Tax effect	167				(176		)		165
		(256		)		260				(350		)
	Other postretirement benefit plans
	Unrecognized net actuarial loss and transition amount	(36		)		65				(32		)
	Unrecognized prior service cost/credit	—				(3		)		(2		)
	Tax effect	14				(24		)		12
		(22		)		38				(22		)
	Cash flow hedges and other
	Recognition of effective portion of hedges	18				37				(20		)
	Amortization included in net income	(5		)		(10		)		—
	Currency and other	2				4				(1		)
		15				31				(21		)
	Tax effect	3				(13		)		5
		18				18				(16		)
	Spin-off of health care business	9				—				—
	Change in AOCI	$	(1,070	)		$	(183	)		$	(193	)
	Amounts are reclassified from AOCI into cost of products sold, marketing, research and general expenses, interest expense or other (income) and expense, net, as applicable, in the Consolidated Income Statement.
	Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in AOCI. For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation adjustments are recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation adjustment would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation. The change in unrealized translation in 2014 is primarily due to the strengthening of the U.S. dollar versus the Australian dollar, Colombian peso, Russian ruble, euro, Brazilian real and British pound sterling, as well as most other foreign currencies. Also included in unrealized translation amounts are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments.

Leases_and_Commitments

Leases and Commitments	12 Months Ended
	Dec. 31, 2014
Leases and Commitments
Leases and Commitments	Leases and Commitments
	We have entered into operating leases for certain warehouse facilities, automobiles and equipment. The future minimum obligations under operating leases having a noncancelable term in excess of one year are as follows:
		Year Ending December 31
	2015	$	151
	2016	117
	2017	94
	2018	70
	2019	56
	Thereafter	99
	Future minimum obligations	$	587
	Consolidated rental expense under operating leases was $303, $316 and $303 in 2014, 2013 and 2012, respectively.
	We have entered into long-term contracts for the purchase of superabsorbent materials, pulp and certain utilities. Commitments under these contracts based on current prices are $297 in 2015, $187 in 2016, $165 in 2017, $141 in 2018 and $147 in 2019. Total commitments beyond the year 2019 are $163.
	Although we are primarily liable for payments on the above-mentioned leases and purchase commitments, our exposure to losses, if any, under these arrangements is not material.

Legal_Matters

Legal Matters	12 Months Ended
	Dec. 31, 2014
Legal Matters
Legal Matters	Legal Matters
	We are subject to various legal proceedings, claims and governmental inquiries, inspections, audits or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, pricing, business practices, governmental regulations, employment and other matters. Although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, individually or in the aggregate, on our business, financial condition, results of operations or liquidity.
	We are subject to federal, state and local environmental protection laws and regulations with respect to our business operations and are operating in compliance with, or taking action aimed at ensuring compliance with, these laws and regulations. We have been named a potentially responsible party under the provisions of the U.S. federal Comprehensive Environmental Response, Compensation and Liability Act, or analogous state statutes, at a number of sites where hazardous substances are present. None of our compliance obligations with environmental protection laws and regulations, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition, results of operations or liquidity.

Objectives_and_Strategies_for_

Objectives and Strategies for Using Derivatives	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Objectives and Strategies for Using Derivatives	Objectives and Strategies for Using Derivatives
	As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments. We enter into derivative instruments to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated and qualify as cash flow hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments.
	Interest rate risk is managed using a portfolio of variable- and fixed-rate debt composed of short- and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable- and fixed-rate debt and are designated and qualify as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, using forward-starting swaps, and these contracts are designated as cash flow hedges.
	We use derivative instruments, such as forward swap contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months.
	Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowing. Translation exposure, which results from changes in translation rates between functional currencies and the U.S. dollar, generally is not hedged.
	Set forth below is a summary of the total designated and undesignated fair values of our derivative instruments:
		Assets				Liabilities
		2014		2013		2014		2013
	Foreign currency exchange contracts	$	54	$	34	$	102	$	49
	Interest rate contracts	—		22		4		—
	Commodity price contracts	—		6		10		—
	Total	$	54	$	62	$	116	$	49
	The derivative assets are included in the Consolidated Balance Sheet in other current assets and other assets, as appropriate. The derivative liabilities are included in the Consolidated Balance Sheet in accrued expenses and other liabilities, as appropriate.
	Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in current earnings. The offset to the change in fair values of the related hedged items also is recorded in current earnings. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to interest expense over the life of the related debt. At December 31, 2014, the aggregate notional values of outstanding interest rate contracts designated as fair value hedges were $250. Fair value hedges resulted in no significant ineffectiveness in each of the three years ended December 31, 2014. For each of the three years ended December 31, 2014, gains or losses recognized in interest expense for interest rates swaps were not significant. For each of the three years ended December 31, 2014, no gain or loss was recognized in earnings as a result of a hedged firm commitment no longer qualifying as a fair value hedge.
	For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same period that the hedged exposure affects earnings. As of December 31, 2014, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in 2015 and future periods. As of December 31, 2014, the aggregate notional values of outstanding foreign exchange and interest rate derivative contracts designated as cash flow hedges were $820 and $200, respectively. Cash flow hedges resulted in no significant ineffectiveness in each of the three years ended December 31, 2014. For each of the three years ended December 31, 2014, no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecast transaction no longer being probable of occurring. At December 31, 2014, amounts to be reclassified from AOCI during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at December 31, 2014 is December 2017.
	Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in other (income) and expense, net. Losses of $192 and $74 and gains of $69 were recorded in the years ending December 31, 2014, 2013 and 2012, respectively. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At December 31, 2014, the notional amount of these undesignated derivative instruments was $2.6 billion.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	An analysis of the provision for income taxes follows:
		Year Ended December 31
		2014				2013				2012
	Current income taxes
	United States	$	350			$	292			$	112
	State	48				99				15
	Other countries	387				286				289
	Total	785				677				416
	Deferred income taxes
	United States	67				85				218
	State	(16		)		14				36
	Other countries	20				52				(10		)
	Total	71				151				244
	Total provision for income taxes	$	856			$	828			$	660
	Income from continuing operations before income taxes is earned in the following tax jurisdictions:
		Year Ended December 31
		2014				2013				2012
	United States	$	1,571			$	1,557			$	1,223
	Other countries	684				1,084				887
	Total income before income taxes	$	2,255			$	2,641			$	2,110
	Deferred income tax assets and liabilities are composed of the following:
			31-Dec
			2014				2013
	Deferred tax assets
	Pension and other postretirement benefits		$	883			$	728
	Tax credits and loss carryforwards		538				604
	Property, plant and equipment, net		77				104
	Other		590				516
			2,088				1,952
	Valuation allowance		(215		)		(197		)
	Total deferred assets		1,873				1,755
	Deferred tax liabilities
	Pension and other postretirement benefits		260				259
	Property, plant and equipment, net		1,162				1,244
	Investments in subsidiaries		223				205
	Other		339				396
	Total deferred tax liabilities		1,984				2,104
	Net deferred tax assets (liabilities)		$	(111	)		$	(349	)
	Valuation allowances at the end of 2014 primarily relate to tax credits and income tax loss carryforwards of $1.0 billion. If these items are not utilized against taxable income, $445 of the loss carryforwards will expire from 2015 through 2034. The remaining $557 have no expiration date.
	Realization of income tax loss carryforwards is dependent on generating sufficient taxable income prior to expiration of these carryforwards. Although realization is not assured, we believe it is more likely than not that all of the deferred tax assets, net of applicable valuation allowances, will be realized. The amount of the deferred tax assets considered realizable could be reduced or increased due to changes in the tax environment or if estimates of future taxable income change during the carryforward period.
	Presented below is a reconciliation of the income tax provision computed at the U.S. federal statutory tax rate to the actual effective tax rate:
		Year Ended December 31
		2014			2013			2012
	U.S. statutory rate applied to income before income taxes	35	%		35	%		35	%
	Rate of state income taxes, net of federal tax benefit	0.7			2.7			1.6
	Statutory rates other than U.S. statutory rate	(3.0	)		(3.0	)		(2.8	)
	Venezuela balance sheet remeasurement and inflationary impacts	4.9			(0.8	)		(0.4	)
	Other - net(a)	0.4			(2.5	)		(2.1	)
	Effective income tax rate	38	%		31.4	%		31.3	%
	(a)	Other - net is composed of numerous items, none of which is greater than 1.75 percent of income before income taxes.
	At December 31, 2014, U.S. income taxes and foreign withholding taxes have not been provided on $8.6 billion of unremitted earnings of subsidiaries operating outside the U.S. These earnings, which are considered to be invested indefinitely, would become subject to income tax if they were remitted as dividends, were lent to one of our U.S. entities, or if we were to sell our stock in the subsidiaries. Determination of the amount of unrecognized deferred U.S. income tax liability on these unremitted earnings is not practicable because of the complexities associated with this hypothetical calculation. We do not expect restrictions or taxes on repatriation of cash held outside of the United States to have a material effect on our overall liquidity, financial condition or results of operations in the foreseeable future.
	Presented below is a reconciliation of the beginning and ending amounts of unrecognized income tax benefits:
		2014				2013				2012
	Balance at January 1	$	473			$	435			$	558
	Gross increases for tax positions of prior years	36				73				30
	Gross decreases for tax positions of prior years	(91		)		(31		)		(104		)
	Gross increases for tax positions of the current year	87				37				52
	Settlements	(77		)		(35		)		(100		)
	Other	(12		)		(6		)		(1		)
	Balance at December 31	$	416			$	473			$	435
	Of the amounts recorded as unrecognized tax benefits at December 31, 2014, $266 would reduce our effective tax rate if recognized.
	We recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2014, 2013 and 2012, the net cost in interest and penalties was not significant. Total accrued penalties and net accrued interest was $28 and $42 at December 31, 2014 and 2013, respectively.
	It is reasonably possible that a number of uncertainties could be resolved within the next 12 months, the most significant of which involves tax credits. It is reasonably possible the aggregate resolution of the uncertainties could be up to $130, while none of the uncertainties is individually significant. Resolution of these matters is not expected to have a material effect on our financial condition, results of operations or liquidity.
As of December 31, 2014, the following tax years remain subject to examination for the major jurisdictions where we conduct business:
Jurisdiction	Years
United States	2012 to 2014
United Kingdom	2012 to 2014
Brazil	2009 to 2014
Korea	2014
China	2003 to 2014
Our U.S. federal income tax returns have been audited through 2011. We have various federal income tax return positions in administrative appeals or litigation for 1999 to 2011.
State income tax returns are generally subject to examination for a period of 3 to 5 years after filing of the respective return. The state effect of any changes to filed federal positions remains subject to examination by various states for a period of up to two years after formal notification to the states. We have various state income tax return positions in the process of examination, administrative appeals or litigation.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share ("EPS")
	There are no adjustments required to be made to net income for purposes of computing basic and diluted EPS. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows:
	(Millions of shares)		2014	2013		2012
	Basic		374.5	384		393
	Dilutive effect of stock options and restricted share unit awards		2.9	3.3		3.1
	Diluted		377.4	387.3		396.1
	Options outstanding that were not included in the computation of diluted EPS mainly because their exercise price was greater than the average market price of the common shares are summarized below:
		2014		2013			2012
	Average number of share equivalents (millions)	1.1		1.1			1.1
	Weighted-average exercise price	$	107.54	$	103.29		$	78.54
	Options outstanding at year-end (millions)	1.7		1.8			1.7
	The weighted-average exercise price for 2014 has been converted to reflect the impact on outstanding stock options as a result of the spin-off of our health care business. The number of common shares outstanding as of December 31, 2014, 2013 and 2012 was 365.3 million, 380.8 million and 389.3 million, respectively.

Description_of_Business_Segmen

Description of Business Segments	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information
	We are organized into operating segments based on product groupings. These operating segments have been aggregated into three reportable global business segments: Personal Care, Consumer Tissue and KCP. The reportable segments were determined in accordance with how our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes other (income) and expense, net and income and expense not associated with the business segments, including the charges related to the 2014 organization restructuring, the European strategic changes and the pulp and tissue restructuring actions described in Notes 3, 4 and 5, respectively.
	The principal sources of revenue in each global business segment are described below:
	•	Personal Care brands offer parents a trusted partner in caring for their families and deliver confidence, protection and discretion to adults through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Kotex, U by Kotex, Intimus, Depend, Plenitud, Poise and other brand names.
	•	Consumer Tissue offers a wide variety of innovative solutions and trusted brands that touch and improve people's lives every day.  Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve and other brand names.
	•	K-C Professional helps transform workplaces for employees and patrons, making them healthier, safer and more productive, through a range of solutions and supporting products such as apparel, wipers, soaps, sanitizers, tissue and towels.  Key brands in this segment include Kleenex, Scott, WypAll, Kimtech and Jackson Safety.
	Net sales to Wal-Mart Stores, Inc. were approximately 13 percent in 2014, 2013 and 2012.
	Information concerning consolidated operations by business segment is presented in the following tables:
	Consolidated Operations by Business Segment
		Year Ended December 31
		2014			2013			2012
	NET SALES(a)
	Personal Care	$	9,635		$	9,536		$	9,576
	Consumer Tissue	6,645			6,637			6,527
	K-C Professional	3,388			3,323			3,283
	Corporate & Other	56			65			81
	TOTAL NET SALES	$	19,724		$	19,561		$	19,467
	OPERATING PROFIT(b)
	Personal Care	$	1,803		$	1,698		$	1,660
	Consumer Tissue	1,062			988			887
	K-C Professional	604			605			542
	Corporate & Other(c)	(495		)	(381		)	(717		)
	Other (income) and expense, net(c)	453			7			(5		)
	TOTAL OPERATING PROFIT	$	2,521		$	2,903		$	2,377
	(a)	Net sales in the United States to third parties totaled $8,573, $8,557 and $8,514 in 2014, 2013 and 2012, respectively.
	(b)	Segment operating profit excludes other (income) and expense, net and income and expenses not associated with the business segments.
	(c)	Corporate & Other and other (income) and expense, net include the following charges:
			Year Ended December 31
			2014			2013			2012
			European			European			European			Pulp and Tissue			Total
			Strategic			Strategic			Strategic			Restructuring
			Changes			Changes			Changes			Actions
	Personal Care		$	20		$	36		$	213		$	—		$	213
	Consumer Tissue		12			27			66			125			191
	K-C Professional		1			13			20			9			29
	Other (income) and expense, net		—			5			—			1			1
	Total		$	33		$	81		$	299		$	135		$	434
	Corporate & Other also includes charges related to the 2014 organization restructuring of $133 and a charge of $41 related to the remeasurement of the Venezuelan balance sheet in 2014. In addition, other (income) and expense, net for 2014 includes a charge of $35 related to a regulatory dispute in the Middle East, and for 2014 and 2013 includes charges of $421 and $36 related to the remeasurement of the Venezuelan balance sheet, respectively.
		Personal			Consumer			K-C			Corporate			Ongoing			Health Care		Consolidated
		Care			Tissue			Professional			& Other			Operations			Business		Total
																	(Spun-off)
	Depreciation and Amortization
	2014	$	359		$	299		$	132		$	3		$	793		$	69	$	862
	2013	332			318			138			4			792			71		863
	2012	315			331			141			11			798			59		857
	Assets
	2014	6,373			5,229			2,339			1,585			15,526			—		15,526
	2013	6,623			5,483			2,431			2,012			16,549			2,370		18,919
	2012	7,014			5,531			2,739			2,058			17,342			2,531		19,873
	Capital Spending
	2014	501			314			143			6			964			75		1,039
	2013	461			328			118			2			909			44		953
	2012	551			352			116			32			1,051			42		1,093
	Sales of Principal Products
	(Billions of dollars)		2014			2013			2012
	Consumer tissue products		$	6.6		$	6.6		$	6.5
	Baby and child care products		7			7			7.1
	Away-from-home professional products		3.4			3.3			3.3
	All other		2.7			2.7			2.6
	Consolidated		$	19.7		$	19.6		$	19.5

Supplemental_Data

Supplemental Data	12 Months Ended
	Dec. 31, 2014
Supplemental Data
Supplemental Data	Supplemental Data
	Supplemental Income Statement Data
		Year Ended December 31
		2014			2013			2012
	Advertising expense	$	767		$	769		$	804
	Research expense	368			333			335
	Equity Companies' Data
		Net			Gross			Operating			Net			Corporation's
		Sales			Profit			Profit			Income			Share of Net
														Income
	2014	$	2,452		$	781		$	485		$	304		$	146
	2013	2,638			950			642			426			205
	2012	2,514			864			567			368			177
		Current			Non-			Current			Non-			Stockholders'
		Assets			Current			Liabilities			Current			Equity
					Assets						Liabilities
	2014	$	1,016		$	1,040		$	690		$	963		$	403
	2013	1,197			1,124			847			845			629
	2012	1,054			1,068			712			837			573
	Equity companies are principally engaged in operations in the personal care and consumer tissue businesses. At December 31, 2014, our ownership interest in Kimberly-Clark de Mexico, S.A.B. de C.V. and subsidiaries was 47.9%. Kimberly-Clark de Mexico, S.A.B. de C.V. is partially owned by the public, and its stock is publicly traded in Mexico. At December 31, 2014, our investment in this equity company was $194, and the estimated fair value of the investment was $3.4 billion based on the market price of publicly traded shares. Our other equity ownership interests are not significant to our consolidated balance sheet or financial results.
	At December 31, 2014, unremitted net income of equity companies included in consolidated retained earnings was $1.0 billion.
	Supplemental Balance Sheet Data
	See Note 2 for the impact of the spin-off of our health care business on the Consolidated Balance Sheet.
		December 31
	Summary of Accounts Receivable, Net	2014			2013
	From customers	$	2,079		$	2,345
	Other	210			271
	Less allowance for doubtful accounts and sales discounts	(66		)	(71		)
	Total	$	2,223		$	2,545
		December 31
		2014									2013
	Summary of Inventories by Major Class	LIFO			Non-			Total			LIFO			Non-		Total
					LIFO									LIFO
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials	$	104		$	322		$	426		$	143		$	319	$	462
	Work in process	120			95			215			189			97		286
	Finished goods	511			672			1,183			648			753		1,401
	Supplies and other	—			288			288			—			326		326
		735			1,377			2,112			980			1,495		2,475
	Excess of FIFO or weighted-average cost over LIFO cost	(220		)	—			(220		)	(242		)	—		(242		)
	Total	$	515		$	1,377		$	1,892		$	738		$	1,495	$	2,233
		December 31
	Summary of Property, Plant and Equipment, Net	2014			2013
	Land	$	177		$	196
	Buildings	2,574			2,776
	Machinery and equipment	13,437			14,193
	Construction in progress	591			515
		16,779			17,680
	Less accumulated depreciation	(9,420		)	(9,732		)
	Total	$	7,359		$	7,948
	Property, plant and equipment, net in the United States as of December 31, 2014 and 2013 was $3,685 and $3,917, respectively.
		December 31
	Summary of Accrued Expenses	2014			2013
	Accrued advertising and promotion	$	326		$	355
	Accrued salaries and wages	415			471
	Accrued rebates	258			358
	Accrued taxes - income and other	330			336
	Derivatives	113			44
	Other	532			496
	Total	$	1,974		$	2,060
	Supplemental Cash Flow Statement Data
	Summary of Cash Flow Effects of Decrease (Increase) in Operating Working Capital	Year Ended December 31
		2014			2013			2012
	Accounts receivable	$	267		$	4		$	(38	)
Inventories	12			100			9
Trade accounts payable	(30		)	128			45
Accrued expenses	(120		)	(177		)	133
Accrued income taxes	(159		)	(90		)	13
Derivatives	103			5			(86		)
Currency and other	(249		)	(128		)	43
Total	$	(176	)	$	(158	)	$	119
	Year Ended December 31
Other Cash Flow Data	2014			2013			2012
Interest paid	$	300		$	307		$	299
Income taxes paid	926			776			451

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
	FOR THE YEARS ENDED DECEMBER 31, 2014, 2013 AND 2012
	(Millions of dollars)
	Description	Balance at		Additions						Deductions
		Beginning
		of Period		Charged to			Charged to			Write-Offs and				Balance
				Costs and			Other			Reclassifications				at End of
				Expenses			Accounts(a)							Period
	December 31, 2014
	Allowances deducted from assets to which they apply
	Allowance for doubtful accounts	$	51	$	13		$	(7	)	$	7		(b)	$	50
	Allowances for sales discounts	20		265			(1		)	268			(c)	16
	December 31, 2013
	Allowances deducted from assets to which they apply
	Allowance for doubtful accounts	$	60	$	—		$	(4	)	$	5		(b)	$	51
	Allowances for sales discounts	20		275			(1		)	274			(c)	20
	December 31, 2012
	Allowances deducted from assets to which they apply
	Allowance for doubtful accounts	$	57	$	9		$	—		$	6		(b)	$	60
	Allowances for sales discounts	21		280			—			281			(c)	20
	(a)	Includes bad debt recoveries and the effects of changes in foreign currency exchange rates.
	(b)	Primarily uncollectible receivables written off.
	(c)	Sales discounts allowed.
				Additions
	Description	Balance at		Charged to			Charged to			Deductions(a)				Balance
		Beginning		Costs and			Other							at End
		of Period		Expenses			Accounts							of  Period
	December 31, 2014
	Deferred taxes
	Valuation allowance	$	197	$	30		$	—		$	12			$	215
	December 31, 2013
	Deferred taxes
	Valuation allowance	$	215	$	(11	)	$	—		$	7			$	197
	December 31, 2012
	Deferred taxes
	Valuation allowance	$	229	$	(18	)	$	—		$	(4	)		$	215
	(a)	Represents the net currency effects of translating valuation allowances at current rates of exchange.

Accounting_Policies_Policy

Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Actual results could differ from these estimates, and changes in these estimates are recorded when known. Estimates are used in accounting for, among other things, sales incentives and trade promotion allowances, employee postretirement benefits, and deferred income taxes and potential assessments.
Cash Equivalents	Cash Equivalents
	Cash equivalents are short-term investments with an original maturity date of three months or less.
Inventories and Distribution Costs	Inventories and Distribution Costs
	Most U.S. inventories are valued at the lower of cost, using the Last-In, First-Out (LIFO) method, or market. The balance of the U.S. inventories and inventories of consolidated operations outside the U.S. are valued at the lower of cost, using either the First-In, First-Out (FIFO) or weighted-average cost methods, or market. Distribution costs are classified as cost of products sold.
Property and Depreciation	Property and Depreciation
	Property, plant and equipment are stated at cost and are depreciated on the straight-line method. Buildings are depreciated over their estimated useful lives, primarily 40 years. Machinery and equipment are depreciated over their estimated useful lives, primarily ranging from 16 to 20 years. Purchases of computer software, including external costs and certain internal costs (including payroll and payroll-related costs of employees) directly associated with developing significant computer software applications for internal use, are capitalized. Computer software costs are amortized on the straight-line method over the estimated useful life of the software, which generally does not exceed 5 years.
	Estimated useful lives are periodically reviewed and, when warranted, changes are made to them. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss would be indicated when estimated undiscounted future cash flows from the use and eventual disposition of an asset group, which are identifiable and largely independent of the cash flows of other asset groups, are less than the carrying amount of the asset group. Measurement of an impairment loss would be based on the excess of the carrying amount of the asset group over its fair value. Fair value is measured using discounted cash flows or independent appraisals, as appropriate. When property is sold or retired, the cost of the property and the related accumulated depreciation are removed from the Consolidated Balance Sheet and any gain or loss on the transaction is included in income.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets
	Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Goodwill is not amortized, but rather is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. Impairment testing compares the reporting unit carrying amount of goodwill with its fair value. Fair value is estimated based on discounted cash flows. If the reporting unit carrying amount of goodwill exceeds its fair value, an impairment charge would be recorded. For 2014, we have completed the required annual testing of goodwill for impairment for all reporting units using the first day of the third quarter as the measurement date, and have determined that goodwill is not impaired.
	Intangible assets with finite lives are amortized over their estimated useful lives and are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Estimated useful lives range from 2 to 20 years for trademarks, 5 to 15 years for patents and developed technologies, and 5 to 15 years for other intangible assets. An impairment loss would be indicated when estimated undiscounted future cash flows from the use of the asset are less than its carrying amount. An impairment loss would be measured as the difference between the fair value (based on discounted future cash flows) and the carrying amount of the asset.
Investments in Equity Companies	Investments in Equity Companies
	Investments in companies which we do not control but over which we have the ability to exercise significant influence and that, in general, are at least 20 percent-owned by us, are stated at cost plus equity in undistributed net income. These investments are evaluated for impairment when warranted. An impairment loss would be recorded whenever a decline in value of an equity investment below its carrying amount is determined to be other than temporary. In judging "other than temporary," we would consider the length of time and extent to which the fair value of the equity company investment has been less than the carrying amount, the near-term and longer-term operating and financial prospects of the equity company, and our longer-term intent of retaining the investment in the equity company.
Revenue Recognition	Revenue Recognition
	Sales revenue is recognized at the time of product shipment or delivery, depending on when title passes, to unaffiliated customers, and when all of the following have occurred: a firm sales agreement is in place, pricing is fixed or determinable, and collection is reasonably assured. Sales are reported net of returns, consumer and trade promotions, rebates and freight allowed. Taxes imposed by governmental authorities on our revenue-producing activities with customers, such as sales taxes and value-added taxes, are excluded from net sales.
Sales Incentives and Trade Promotion Allowances	Sales Incentives and Trade Promotion Allowances
	The cost of promotion activities provided to customers is classified as a reduction in sales revenue. In addition, the estimated redemption value of consumer coupons is recorded at the time the coupons are issued and classified as a reduction in sales revenue. Estimates of trade promotion liabilities for promotional program costs incurred, but unpaid, are generally based on estimates of the quantity of customer sales, timing of promotional activities and forecasted costs for activities within the promotional programs.
Advertising Expense	Advertising Expense
	Advertising costs are expensed in the year the related advertisement or campaign is first presented by the media. For interim reporting purposes, advertising expenses are charged to operations as a percentage of sales based on estimated sales and related advertising expense for the full year.
Research Expense	Research Expense
	Research and development costs are charged to expense as incurred.
Foreign Currency Translation	Foreign Currency Translation
	The income statements of foreign operations, other than those in highly inflationary economies, are translated into U.S. dollars at rates of exchange in effect each month. The balance sheets of these operations are translated at period-end exchange rates, and the differences from historical exchange rates are reflected in stockholders' equity as unrealized translation adjustments.
	The income statements and balance sheets of operations in highly inflationary economies are translated into U.S. dollars using both current and historical rates of exchange. We account for our operations in Venezuela using highly inflationary accounting.
Derivative Instruments and Hedging	While we continue to seek approval for additional imports at the official rate, unless we are able to obtain further approvals for imports through approved letters of credit or through the official government exchange system, we may be forced to curtail some or all of our local manufacturing in the future until such approvals to import additional raw materials are forthcoming. In January 2015, we measured results in Venezuela at the floating SICAD II exchange rate. In mid-February 2015, the government of Venezuela announced changes to their three-tiered currency exchange system. We are evaluating the implications of these changes to assess the impact on our results and reporting for our operations in that country.
	Derivative Instruments and Hedging
	Our policies allow the use of derivatives for risk management purposes and prohibit their use for speculation. Our policies also prohibit the use of any leveraged derivative instrument. Consistent with our policies, foreign currency derivative instruments, interest rate swaps and locks, and the majority of commodity hedging contracts are entered into with major financial institutions. At inception we formally designate certain derivatives as cash flow, fair value or net investment hedges and establish how the effectiveness of these hedges will be assessed and measured. This process links the derivatives to the transactions or financial balances they are hedging. Changes in the fair value of derivatives not designated as hedging instruments are recorded in earnings as they occur. All derivative instruments are recorded as assets or liabilities on the balance sheet at fair value. Changes in the fair value of derivatives are either recorded in the income statement or other comprehensive income, as appropriate. The gain or loss on derivatives designated as fair value hedges and the offsetting loss or gain on the hedged item attributable to the hedged risk are included in income in the period that changes in fair value occur. The effective portion of the gain or loss on derivatives designated as cash flow hedges is included in other comprehensive income in the period that changes in fair value occur, and is reclassified to income in the same period that the hedged item affects income. The gain or loss on derivatives designated as hedges of investments in foreign subsidiaries is recognized in other comprehensive income to offset the change in value of the net investments being hedged. Any ineffective portion of cash flow hedges and net investment hedges is immediately recognized in income. Certain foreign-currency derivative instruments not designated as hedging instruments have been entered into to manage a portion of our foreign currency transactional exposures. The gain or loss on these derivatives is included in income in the period that changes in their fair values occur.

Spinoff_of_Health_Care_Busines1

Spinoff of Health Care Business and Related Costs (Tables) (Health Care Spin-off [Member])	12 Months Ended
	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Summary of the spun-off of the health care business [Table Text Block]	In connection with the spin-off, we transferred the following assets and liabilities to Halyard:
	Assets
	Cash	$	120
	Accounts receivable, net	37
	Inventories	289
	Property, plant and equipment, net	271
	Goodwill	1,429
	Other intangible assets	114
	Other assets	66
	Total Assets	$	2,326
	Liabilities
	Accrued expenses	$	127
	Debt	636
	Deferred income taxes	60
	Other liabilities	7
	Total Liabilities	$	830
	Net Assets Transferred in the Spin-Off	$	1,496
Operations of health care business included in health care business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Summary of the spun-off of the health care business [Table Text Block]	Summary results of operations for the spun-off health care business included in net income from discontinued operations, net of income taxes, were as follows:
		Year Ended December 31
		2014			2013			2012
	Net sales	$	1,320		$	1,591		$	1,596
	Income before income taxes	130			304			310
	Provision for income taxes	(80		)	(101		)	(109		)
	Net income	50			203			201

2014_Organization_Restructurin1

2014 Organization Restructuring (Tables) (2014 Organization Restructuring [Member])	12 Months Ended
	Dec. 31, 2014
2014 Organization Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Charges incurred in connection with restructuring	Charges in the fourth quarter of 2014 were $133, recorded in the following income statement line items:
		2014
	Cost of products sold	$	40
	Marketing, research and general expenses	93
	Provision for income taxes	(38		)
	Net charges	$	95

European_Strategic_Changes_Tab

European Strategic Changes (Tables) (European Strategic Changes [Member])	12 Months Ended
	Dec. 31, 2014
European Strategic Changes [Member]
Restructuring Cost and Reserve
Charges incurred in connection with restructuring	The following charges were incurred in connection with the European strategic changes:
		Year Ended December 31
		2014			2013			2012
	Asset impairments and other asset-related charges	$	2		$	53		$	165
	Charges for workforce reductions	(5		)	10			77
	Benefit from pension curtailment	—			(31		)	—
	Other exit costs	14			22			8
	Cost of products sold	11			54			250
	Charges for workforce reductions and other exit costs included in marketing, research and general expenses and other (income) and expense, net	22			27			49
	Provision for income taxes	(3		)	(15		)	(57		)
	Net charges	$	30		$	66		$	242

Fair_Value_Information_Tables

Fair Value Information (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair value of financial instruments	The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
		Fair Value	Carrying		Estimated		Carrying		Estimated
		Hierarchy	Amount		Fair		Amount		Fair
		Level			Value				Value
			December 31, 2014				December 31, 2013
	Assets
	Cash and cash equivalents(a)	1	$	789	$	789	$	1,054	$	1,054
	Time deposits(b)	1	130		130		222		222
	Liabilities and redeemable securities of subsidiaries
	Short-term debt(c)	2	777		777		63		63
	Long-term debt(d)	2	6,179		6,963		5,698		6,721
	Redeemable securities of subsidiaries(e)	3	72		72		578		598
	(a)	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
	(b)	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
	(c)	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
	(d)	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
	(e)	The redeemable securities of subsidiaries are not traded in active markets. For certain instruments, fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest or dividend payment dates. Additionally, the fair value of the remaining redeemable securities was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Acquisitions_and_Intangible_As1

Acquisitions and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill by business segment are as follows:
		Personal			Consumer			K-C			Health Care			Total
		Care			Tissue			Professional			Business
	Balance at December 31, 2012	$	764		$	695		$	442		$	1,436		$	3,337
	Acquisitions	6			—			—			3			9
	Currency and other	(86		)	(54		)	(18		)	(7		)	(165		)
	Balance at December 31, 2013	684			641			424			1,432			3,181
	Currency and other	(59		)	(47		)	(15		)	(3		)	(124		)
	Spin-off of health care business	—			—			—			(1,429		)	(1,429		)
	Balance at December 31, 2014	$	625		$	594		$	409		$	—		$	1,628
Intangible assets subject to amortization	Intangible assets subject to amortization consist of the following at December 31:
		2014						2013
		Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Amount						Amount
	Trademarks	$	117		$	79		$	252		$	163
	Patents and developed technologies	49			9			201			85
	Other	64			33			93			62
	Total	$	230		$	121		$	546		$	310

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-term debt	Long-term debt is composed of the following:
		Weighted-	Maturities	December 31
		Average
		Interest
		Rate		2014		2013
	Notes and debentures	4.70%	2015 - 2043	$	5,656	$	5,163
	Dealer remarketable securities	4.30%	2015 - 2016	200		200
	Industrial development revenue bonds	0.20%	2015 - 2034	261		261
	Bank loans and other financings in various currencies	5.80%	2015 - 2025	62		74
	Total long-term debt			6,179		5,698
	Less current portion			549		312
	Long-term portion			$	5,630	$	5,386

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation [Abstract]
Schedule of weighted-average fair value of options, assumptions used	The weighted-average fair value of options granted was estimated at $7.89, $7.15 and $3.25, in 2014, 2013 and 2012, respectively, per option on the date of grant based on the following assumptions:
		Year Ended December 31
		2014		2013		2012
	Dividend yield	3.5	%	3.7	%	4.5	%
	Volatility	13.41	%	15.4	%	12.86	%
	Risk-free interest rate	1.73	%	0.87	%	1.08	%
	Expected life—years	5		5.1		5.8
Schedule of total remaining unrecognized compensation costs and amortization period	Total remaining unrecognized compensation costs and amortization period are as follows:
		December 31, 2014			Weighted-
					Average
					Service
					Years
	Nonvested stock options	$	8		1
	Restricted shares and time-vested restricted share units	5			0.5
	Nonvested performance-based restricted share units	44			1.2
Summary of stock-based compensation	A summary of stock-based compensation is presented below:
	Stock Options	Shares		Weighted-			Weighted-		Aggregate
		(in thousands)		Average			Average		Intrinsic
				Exercise			Remaining		Value
				Price			Contractual
							Term
	Outstanding at January 1, 2014	7,223		$	75.77
	Granted	1,798		112.26
	Exercised	(1,860	)	68.02
	Forfeited or expired	(506	)	97.57
	Conversion for spin-off of health care business	306		82.26
	Outstanding at December 31, 2014	6,961		82.32			6.51		$	231
	Exercisable at December 31, 2014	3,846		68.26			4.76		$	182
Summary of nonvested restricted share units
		Time-Vested					Performance-Based
		Restricted Share					Restricted Share
		Units					Units
	Other Stock-Based Awards	Shares		Weighted-			Shares			Weighted-
		(in thousands)		Average			(in thousands)			Average
				Grant-Date						Grant-Date
				Fair Value						Fair Value
	Nonvested at January 1, 2014	257		$	81.38		2,083			$	79.98
	Granted	73		100.95			842			111.77
	Vested	(70	)	81.97			(894	)		65.02
	Forfeited	(38	)	84.01			(301	)		94.73
	Dividend equivalent for spin-off of health care business	22		78.04			79			95.8
	Nonvested at December 31, 2014	244		86.34			1,809			96.35

Employee_Postretirement_Benefi1

Employee Postretirement Benefits (Tables)	12 Months Ended
	Dec. 31, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Benefit Cost Information or Defined Benefit Plan and Other Postretirement Benefit Plan	Summarized financial information about postretirement plans, excluding defined contribution retirement plans, is presented below:
		Pension Benefits								Other Benefits
		Year Ended December 31
		2014				2013				2014			2013
	Change in Benefit Obligation
	Benefit obligation at beginning of year	$	6,164			$	6,590			$	761		$	824
	Service cost	46				53				13			17
	Interest cost	279				257				35			32
	Actuarial loss (gain)	986				(422		)		39			(60		)
	Currency and other	(207		)		47				(4		)	—
	Benefit payments from plans	(356		)		(343		)		—			—
	Direct benefit payments	(10		)		(13		)		(56		)	(52		)
	Curtailments and settlements	(42		)		(5		)		—			—
	Benefit obligation at end of year	6,860				6,164				788			761
	Change in Plan Assets
	Fair value of plan assets at beginning of year	5,567				5,375				—			—
	Actual return on plan assets	694				268				—			—
	Employer contributions	185				220				—			—
	Currency and other	(142		)		47				—			—
	Benefit payments	(356		)		(343		)		—			—
	Settlements	(34		)		—				—			—
	Fair value of plan assets at end of year	5,914				5,567				—			—
	Funded Status	$	(946	)		$	(597	)		$	(788	)	$	(761	)
	Amounts Recognized in the Balance Sheet
	Noncurrent asset—prepaid benefit cost	$	6			$	9			$	—		$	—
	Current liability—accrued benefit cost	(13		)		(12		)		(51		)	(56		)
	Noncurrent liability—accrued benefit cost	(939		)		(594		)		(737		)	(705		)
	Net amount recognized	$	(946	)		$	(597	)		$	(788	)	$	(761	)
Principal Plans and all Other Pension Plans
		Principal Plans								All Other							Total
										Pension Plans
		Year Ended December 31
		2014				2013				2014			2013				2014				2013
	Projected benefit obligation (“PBO”)	$	6,312			$	5,640			$	548		$	524			$	6,860			$	6,164
	Accumulated benefit obligation (“ABO”)	6,221				5,555				475			439				6,696				5,994
	Fair value of plan assets	5,559				5,205				355			362				5,914				5,567
Pension Plans with an ABO in Excess of Plan Assets
		December 31
		2014				2013
	PBO	$	4,983			$	5,722
	ABO	4,908				5,622
	Fair value of plan assets	4,111				5,163
Components of Net Periodic Benefit Cost
		Pension Benefits											Other Benefits
		Year Ended December 31
		2014				2013				2012			2014				2013				2012
	Service cost	$	46			$	53			$	45		$	13			$	17			$	15
	Interest cost	279				257				279			35				32				36
	Expected return on plan assets(a)	(332		)		(331		)		(329		)	—				—				—
	Recognized net actuarial loss	100				120				111			—				3				1
	Curtailments and settlements	20				(31		)		20			—				—				—
	Other	(3		)		1				(4		)	(1		)		(2		)		(1		)
	Net periodic benefit cost	$	110			$	69			$	122		$	47			$	50			$	51
	(a)	The expected return on plan assets is determined by multiplying the fair value of plan assets at the remeasurement date, typically the prior year-end adjusted for estimated current year cash benefit payments and contributions, by the expected long-term rate of return.
Weighted-Average Assumptions Used to Determine Net Cost
		Pension Benefits											Other Benefits
		Projected 2015			2014			2013			2012		2014			2013			2012
	Discount rate	3.83	%		4.66	%		4.04	%		4.87	%	4.97	%		3.97	%		4.7	%
	Expected long-term return on plan assets	5.21	%		5.98	%		6.26	%		6.49	%	—			—			—
	Rate of compensation increase	2.63	%		2.67	%		2.73	%		2.91	%	—			—			—
Weighted-Average Assumptions Used to Determine Benefit Obligations
		Pension Benefits						Other Benefits
		2014			2013			2014			2013
	Discount rate	3.83	%		4.66	%		4.28	%		4.97	%
	Rate of compensation increase	2.63	%		2.67	%		—			—
Pension Plan Assets of the Principal Plans Measured at Fair Value
		Fair Value Measurements at December 31, 2014
		Total				Quoted Prices				Significant			Significant Unobservable Inputs (Level 3)
						in Active				Observable
						Markets for				Inputs
						Identical Assets				(Level 2)
						(Level 1)
	Cash and Cash Equivalents
	Held directly	$	28			$	28			$	—		$	—
	Held through mutual and pooled funds	175				9				166			—
	Fixed Income
	Held directly
	U.S. government and municipals	252				71				181			—
	U.S. corporate debt	2,167				—				2,167			—
	U.S. securitized fixed income	6				—				6			—
	Held through mutual and pooled funds
	U.S. corporate debt	149				—				149			—
	International bonds	1,438				—				1,438			—
	Multi-sector	1				1				—			—
	Equity
	Held directly
	U.S. equity	18				18				—			—
	Held through mutual and pooled funds
	U.S. equity	4				4				—			—
	Non-U.S. equity	106				1				105			—
	Global equity	1,186				—				1,186			—
	Other	29				29				—			—
	Total Plan Assets	$	5,559			$	161			$	5,398		$	—
	For the U.S. pension plan, equity option strategies are used when appropriate to reduce the volatility of returns on equity investments.  As of December 31, 2014, the U.S. pension plan had equity options in place with a total notional value of approximately $950, and the fair value of the aggregate options was an asset position of $29.  In addition, Treasury futures contracts are used when appropriate to manage duration targets, and equity futures contracts are used to manage the plan’s investment allocation.  As of December 31, 2014, the U.S. plan had Treasury futures contracts in place with a total notional value of approximately $510 and an insignificant fair value. There were no equity futures contracts in place at December 31, 2014. The U.S. plan had Treasury and equity futures contracts with a total notional value of approximately $320 at December 31, 2013 with an insignificant fair value.
		Fair Value Measurements at December 31, 2013
		Total				Quoted Prices				Significant			Significant Unobservable Inputs (Level 3)
						in Active				Observable
						Markets for				Inputs
						Identical Assets				(Level 2)
						(Level 1)
	Cash and Cash Equivalents
	Held directly	$	33			$	33			$	—		$	—
	Held through mutual and pooled funds	173				34				139			—
	Fixed Income
	Held directly
	U.S. government and municipals	211				71				140			—
	U.S. corporate debt	1,654				—				1,654			—
	U.S. securitized fixed income	8				—				8			—
	Held through mutual and pooled funds
	U.S. corporate debt	186				—				186			—
	International bonds	1,089				—				1,089			—
	Multi-sector	2				2				—			—
	Equity
	Held directly
	U.S. equity	1				1				—			—
	Held through mutual and pooled funds
	U.S. equity	4				4				—			—
	Non-U.S. equity	123				1				122			—
	Global equity	1,691				—				1,691			—
	Other	30				—				—			30
	Total Plan Assets	$	5,205			$	146			$	5,029		$	30
Estimated Future Benefit Payments
		Pension Benefits				Other Benefits
	2015	$	430			$	52
	2016	432				53
	2017	438				55
	2018	440				57
	2019	439				58
	2020-2024	2,181				309
Defined Contribution Pension Plans
		2014				2013				2012
	U.S.	$	87			$	90			$	82
	Outside the U.S.	34				27				26
	Total	$	121			$	117			$	108

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Components of AOCI attributable to Kimberly-Clark	The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:
			Unrealized Translation				Defined Benefit Pension Plans				Other Postretirement Benefit Plans				Cash Flow Hedges and Other
	Balance as of December 31, 2012		$	(26	)		$	(1,928	)		$	(53	)		$	(52	)
	Other comprehensive income (loss) before reclassifications		(499		)		218				36				24
	(Income) loss reclassified from AOCI		—				42			(a)	2			(a)	(6		)
	Net current period other comprehensive income (loss)		(499		)		260				38				18
	Balance as of December 31, 2013		(525		)		(1,668		)		(15		)		(34		)
	Other comprehensive income (loss) before reclassifications		(819		)		(313		)		(23		)		29
	(Income) loss reclassified from AOCI		—				57			(a)	1			(a)	(11		)
	Net current period other comprehensive income (loss)		(819		)		(256		)		(22		)		18
	Spin-off of health care business		9				—				—				—
	Balance as of December 31, 2014		$	(1,335	)		$	(1,924	)		$	(37	)		$	(16	)
	(a)	Included in computation of net periodic pension and postretirement benefits costs (see Note 11)
Change in Components of Accumulated Other Comprehensive Income (Loss)	The changes in the components of AOCI attributable to Kimberly-Clark, including the tax effect, are as follows:
		Year Ended December 31
		2014				2013				2012
	Unrealized translation	$	(826	)		$	(495	)		$	204
	Tax effect	7				(4		)		(9		)
		(819		)		(499		)		195
	Defined benefit pension plans
	Unrecognized net actuarial loss and transition amount
	Funded status recognition	(624		)		356				(588		)
	Amortization included in net periodic benefit cost	100				120				90
	Currency and other	69				(8		)		(20		)
		(455		)		468				(518		)
	Unrecognized prior service cost/credit
	Funded status recognition	42				—				—
	Amortization included in net periodic benefit cost	(7		)		(31		)		—
	Currency and other	(3		)		(1		)		3
		32				(32		)		3
	Tax effect	167				(176		)		165
		(256		)		260				(350		)
	Other postretirement benefit plans
	Unrecognized net actuarial loss and transition amount	(36		)		65				(32		)
	Unrecognized prior service cost/credit	—				(3		)		(2		)
	Tax effect	14				(24		)		12
		(22		)		38				(22		)
	Cash flow hedges and other
	Recognition of effective portion of hedges	18				37				(20		)
	Amortization included in net income	(5		)		(10		)		—
	Currency and other	2				4				(1		)
		15				31				(21		)
	Tax effect	3				(13		)		5
		18				18				(16		)
	Spin-off of health care business	9				—				—
	Change in AOCI	$	(1,070	)		$	(183	)		$	(193	)

Leases_and_Commitments_Tables

Leases and Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Leases and Commitments
Future Minimum Obligations under Operating Leases	The future minimum obligations under operating leases having a noncancelable term in excess of one year are as follows:
		Year Ending December 31
	2015	$	151
	2016	117
	2017	94
	2018	70
	2019	56
	Thereafter	99
	Future minimum obligations	$	587

Objectives_and_Strategies_for_1

Objectives and Strategies for Using Derivatives (Tables)	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of fair values of derivative instruments	Set forth below is a summary of the total designated and undesignated fair values of our derivative instruments:
		Assets				Liabilities
		2014		2013		2014		2013
	Foreign currency exchange contracts	$	54	$	34	$	102	$	49
	Interest rate contracts	—		22		4		—
	Commodity price contracts	—		6		10		—
	Total	$	54	$	62	$	116	$	49

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Analysis of the Provision for Income Taxes	An analysis of the provision for income taxes follows:
		Year Ended December 31
		2014				2013				2012
	Current income taxes
	United States	$	350			$	292			$	112
	State	48				99				15
	Other countries	387				286				289
	Total	785				677				416
	Deferred income taxes
	United States	67				85				218
	State	(16		)		14				36
	Other countries	20				52				(10		)
	Total	71				151				244
	Total provision for income taxes	$	856			$	828			$	660
Income before Income Taxes	Income from continuing operations before income taxes is earned in the following tax jurisdictions:
		Year Ended December 31
		2014				2013				2012
	United States	$	1,571			$	1,557			$	1,223
	Other countries	684				1,084				887
	Total income before income taxes	$	2,255			$	2,641			$	2,110
Deferred Income Tax assets (Liabilities)	Deferred income tax assets and liabilities are composed of the following:
			31-Dec
			2014				2013
	Deferred tax assets
	Pension and other postretirement benefits		$	883			$	728
	Tax credits and loss carryforwards		538				604
	Property, plant and equipment, net		77				104
	Other		590				516
			2,088				1,952
	Valuation allowance		(215		)		(197		)
	Total deferred assets		1,873				1,755
	Deferred tax liabilities
	Pension and other postretirement benefits		260				259
	Property, plant and equipment, net		1,162				1,244
	Investments in subsidiaries		223				205
	Other		339				396
	Total deferred tax liabilities		1,984				2,104
	Net deferred tax assets (liabilities)		$	(111	)		$	(349	)
Reconciliation of Income Tax Provision	Presented below is a reconciliation of the income tax provision computed at the U.S. federal statutory tax rate to the actual effective tax rate:
		Year Ended December 31
		2014			2013			2012
	U.S. statutory rate applied to income before income taxes	35	%		35	%		35	%
	Rate of state income taxes, net of federal tax benefit	0.7			2.7			1.6
	Statutory rates other than U.S. statutory rate	(3.0	)		(3.0	)		(2.8	)
	Venezuela balance sheet remeasurement and inflationary impacts	4.9			(0.8	)		(0.4	)
	Other - net(a)	0.4			(2.5	)		(2.1	)
	Effective income tax rate	38	%		31.4	%		31.3	%
Unrecognized Income Tax Benefits	Presented below is a reconciliation of the beginning and ending amounts of unrecognized income tax benefits:
		2014				2013				2012
	Balance at January 1	$	473			$	435			$	558
	Gross increases for tax positions of prior years	36				73				30
	Gross decreases for tax positions of prior years	(91		)		(31		)		(104		)
	Gross increases for tax positions of the current year	87				37				52
	Settlements	(77		)		(35		)		(100		)
	Other	(12		)		(6		)		(1		)
	Balance at December 31	$	416			$	473			$	435
Summary of Income Tax Examinations	As of December 31, 2014, the following tax years remain subject to examination for the major jurisdictions where we conduct business:
	Jurisdiction	Years
	United States	2012 to 2014
	United Kingdom	2012 to 2014
	Brazil	2009 to 2014
	Korea	2014
	China	2003 to 2014

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Average Common Shares Outstanding Basic and Diluted	The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows:
	(Millions of shares)		2014	2013		2012
	Basic		374.5	384		393
	Dilutive effect of stock options and restricted share unit awards		2.9	3.3		3.1
	Diluted		377.4	387.3		396.1
Options Outstanding not Included in Computation of Diluted EPS	Options outstanding that were not included in the computation of diluted EPS mainly because their exercise price was greater than the average market price of the common shares are summarized below:
		2014		2013			2012
	Average number of share equivalents (millions)	1.1		1.1			1.1
	Weighted-average exercise price	$	107.54	$	103.29		$	78.54
	Options outstanding at year-end (millions)	1.7		1.8			1.7

Business_Segment_and_Geographi

Business Segment and Geographic Data Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting Information [Line Items]
Information Concerning Consolidated Operations by Business Segment	Information concerning consolidated operations by business segment is presented in the following tables:
	Consolidated Operations by Business Segment
		Year Ended December 31
		2014			2013			2012
	NET SALES(a)
	Personal Care	$	9,635		$	9,536		$	9,576
	Consumer Tissue	6,645			6,637			6,527
	K-C Professional	3,388			3,323			3,283
	Corporate & Other	56			65			81
	TOTAL NET SALES	$	19,724		$	19,561		$	19,467
	OPERATING PROFIT(b)
	Personal Care	$	1,803		$	1,698		$	1,660
	Consumer Tissue	1,062			988			887
	K-C Professional	604			605			542
	Corporate & Other(c)	(495		)	(381		)	(717		)
	Other (income) and expense, net(c)	453			7			(5		)
	TOTAL OPERATING PROFIT	$	2,521		$	2,903		$	2,377
	(a)	Net sales in the United States to third parties totaled $8,573, $8,557 and $8,514 in 2014, 2013 and 2012, respectively.
	(b)	Segment operating profit excludes other (income) and expense, net and income and expenses not associated with the business segments.
	(c)	Corporate & Other and other (income) and expense, net include the following charges:
			Year Ended December 31
			2014			2013			2012
			European			European			European			Pulp and Tissue			Total
			Strategic			Strategic			Strategic			Restructuring
			Changes			Changes			Changes			Actions
	Personal Care		$	20		$	36		$	213		$	—		$	213
	Consumer Tissue		12			27			66			125			191
	K-C Professional		1			13			20			9			29
	Other (income) and expense, net		—			5			—			1			1
	Total		$	33		$	81		$	299		$	135		$	434
	Corporate & Other also includes charges related to the 2014 organization restructuring of $133 and a charge of $41 related to the remeasurement of the Venezuelan balance sheet in 2014. In addition, other (income) and expense, net for 2014 includes a charge of $35 related to a regulatory dispute in the Middle East, and for 2014 and 2013 includes charges of $421 and $36 related to the remeasurement of the Venezuelan balance sheet, respectively.
		Personal			Consumer			K-C			Corporate			Ongoing			Health Care		Consolidated
		Care			Tissue			Professional			& Other			Operations			Business		Total
																	(Spun-off)
	Depreciation and Amortization
	2014	$	359		$	299		$	132		$	3		$	793		$	69	$	862
	2013	332			318			138			4			792			71		863
	2012	315			331			141			11			798			59		857
	Assets
	2014	6,373			5,229			2,339			1,585			15,526			—		15,526
	2013	6,623			5,483			2,431			2,012			16,549			2,370		18,919
	2012	7,014			5,531			2,739			2,058			17,342			2,531		19,873
	Capital Spending
	2014	501			314			143			6			964			75		1,039
	2013	461			328			118			2			909			44		953
	2012	551			352			116			32			1,051			42		1,093
Sales of Principal Products
	(Billions of dollars)		2014			2013			2012
	Consumer tissue products		$	6.6		$	6.6		$	6.5
	Baby and child care products		7			7			7.1
	Away-from-home professional products		3.4			3.3			3.3
	All other		2.7			2.7			2.6
	Consolidated		$	19.7		$	19.6		$	19.5

Supplemental_Data_Tables

Supplemental Data (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Income Statement Data	Supplemental Income Statement Data
		Year Ended December 31
		2014			2013			2012
	Advertising expense	$	767		$	769		$	804
	Research expense	368			333			335
Equity Method Investments Data	Equity Companies' Data
		Net			Gross			Operating			Net			Corporation's
		Sales			Profit			Profit			Income			Share of Net
														Income
	2014	$	2,452		$	781		$	485		$	304		$	146
	2013	2,638			950			642			426			205
	2012	2,514			864			567			368			177
		Current			Non-			Current			Non-			Stockholders'
		Assets			Current			Liabilities			Current			Equity
					Assets						Liabilities
	2014	$	1,016		$	1,040		$	690		$	963		$	403
	2013	1,197			1,124			847			845			629
	2012	1,054			1,068			712			837			573
Supplemental Cash Flow Data	Supplemental Cash Flow Statement Data
	Summary of Cash Flow Effects of Decrease (Increase) in Operating Working Capital	Year Ended December 31
		2014			2013			2012
	Accounts receivable	$	267		$	4		$	(38	)
	Inventories	12			100			9
	Trade accounts payable	(30		)	128			45
	Accrued expenses	(120		)	(177		)	133
	Accrued income taxes	(159		)	(90		)	13
	Derivatives	103			5			(86		)
	Currency and other	(249		)	(128		)	43
	Total	$	(176	)	$	(158	)	$	119
		Year Ended December 31
	Other Cash Flow Data	2014			2013			2012
	Interest paid	$	300		$	307		$	299
	Income taxes paid	926			776			451
Accounts Receivable, Net [Member]
Supplemental Balance Sheet Data
		December 31
	Summary of Accounts Receivable, Net	2014			2013
	From customers	$	2,079		$	2,345
	Other	210			271
	Less allowance for doubtful accounts and sales discounts	(66		)	(71		)
	Total	$	2,223		$	2,545
Inventories [Member]
Supplemental Balance Sheet Data
		December 31
		2014									2013
	Summary of Inventories by Major Class	LIFO			Non-			Total			LIFO			Non-		Total
					LIFO									LIFO
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials	$	104		$	322		$	426		$	143		$	319	$	462
	Work in process	120			95			215			189			97		286
	Finished goods	511			672			1,183			648			753		1,401
	Supplies and other	—			288			288			—			326		326
		735			1,377			2,112			980			1,495		2,475
	Excess of FIFO or weighted-average cost over LIFO cost	(220		)	—			(220		)	(242		)	—		(242		)
	Total	$	515		$	1,377		$	1,892		$	738		$	1,495	$	2,233
Property, Plant and Equipment, Net [Member]
Supplemental Balance Sheet Data
		December 31
	Summary of Property, Plant and Equipment, Net	2014			2013
	Land	$	177		$	196
	Buildings	2,574			2,776
	Machinery and equipment	13,437			14,193
	Construction in progress	591			515
		16,779			17,680
	Less accumulated depreciation	(9,420		)	(9,732		)
	Total	$	7,359		$	7,948
Accrued Liabilities [Member]
Supplemental Balance Sheet Data
		December 31
	Summary of Accrued Expenses	2014			2013
	Accrued advertising and promotion	$	326		$	355
	Accrued salaries and wages	415			471
	Accrued rebates	258			358
	Accrued taxes - income and other	330			336
	Derivatives	113			44
	Other	532			496
	Total	$	1,974		$	2,060
Other Cash Flow Data and Interest Expense [Member]
Supplemental Cash Flow Data
		Year Ended December 31
	Other Cash Flow Data	2014			2013			2012
	Interest paid	$	300		$	307		$	299
	Income taxes paid	926			776			451

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts [Table Text Block]	KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
	FOR THE YEARS ENDED DECEMBER 31, 2014, 2013 AND 2012
	(Millions of dollars)
	Description	Balance at		Additions						Deductions
		Beginning
		of Period		Charged to			Charged to			Write-Offs and				Balance
				Costs and			Other			Reclassifications				at End of
				Expenses			Accounts(a)							Period
	December 31, 2014
	Allowances deducted from assets to which they apply
	Allowance for doubtful accounts	$	51	$	13		$	(7	)	$	7		(b)	$	50
	Allowances for sales discounts	20		265			(1		)	268			(c)	16
	December 31, 2013
	Allowances deducted from assets to which they apply
	Allowance for doubtful accounts	$	60	$	—		$	(4	)	$	5		(b)	$	51
	Allowances for sales discounts	20		275			(1		)	274			(c)	20
	December 31, 2012
	Allowances deducted from assets to which they apply
	Allowance for doubtful accounts	$	57	$	9		$	—		$	6		(b)	$	60
	Allowances for sales discounts	21		280			—			281			(c)	20
	(a)	Includes bad debt recoveries and the effects of changes in foreign currency exchange rates.
	(b)	Primarily uncollectible receivables written off.
	(c)	Sales discounts allowed.
				Additions
	Description	Balance at		Charged to			Charged to			Deductions(a)				Balance
		Beginning		Costs and			Other							at End
		of Period		Expenses			Accounts							of  Period
	December 31, 2014
	Deferred taxes
	Valuation allowance	$	197	$	30		$	—		$	12			$	215
	December 31, 2013
	Deferred taxes
	Valuation allowance	$	215	$	(11	)	$	—		$	7			$	197
	December 31, 2012
	Deferred taxes
	Valuation allowance	$	229	$	(18	)	$	—		$	(4	)		$	215
	(a)	Represents the net currency effects of translating valuation allowances at current rates of exchange.

Accounting_Policies_Narrative_

Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended			33 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 01, 2013
Non-deductible remeasurement charge in the Consolidated Income Statement		($462)	-36	0
K-C Venezuela [Member]
Central Bank system rate		6.3			5.4
Devaluation after-tax charge	26
Devaluation pre-tax charge	36
Venezuela effective exchange rate		6.3
SICAD 2 exchange rate		50
Non-deductible remeasurement charge in the Consolidated Income Statement		462
Bolivar-denominated net monetary asset position		59
Net investment in K-C Venezuela		152
K-C Venezuela net sales as a percentage of consolidated net sales		3.00%	2.00%	2.00%
Trademarks [Member] | Minimum [Member]
Intangible assets estimated useful life		2 years
Trademarks [Member] | Maximum [Member]
Intangible assets estimated useful life		20 years
Patents and developed technologies [Member] | Minimum [Member]
Intangible assets estimated useful life		5 years
Patents and developed technologies [Member] | Maximum [Member]
Intangible assets estimated useful life		15 years
Other [Member] | Minimum [Member]
Intangible assets estimated useful life		5 years
Other [Member] | Maximum [Member]
Intangible assets estimated useful life		15 years
Building [Member]
Estimated useful life		40 years
Machinery and Equipment [Member] | Minimum [Member]
Estimated useful life		16 years
Machinery and Equipment [Member] | Maximum [Member]
Estimated useful life		20 years
Software [Member]
Estimated useful life		5 years
Other Income [Member] | K-C Venezuela [Member]
Non-deductible remeasurement charge in the Consolidated Income Statement		421	36
Cost of Sales [Member] | K-C Venezuela [Member]
Non-deductible remeasurement charge in the Consolidated Income Statement		$41

Spinoff_of_Health_Care_Busines2

Spinoff of Health Care Business and Related Costs - Narrative (Details) (Health Care Spin-off [Member], USD $)	10 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Oct. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Health Care Spin-off [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of shares of common stock for one share of Halyard common stock	8
Corporate costs allocated to the health care segment retained in continuing operations	$70	$85	$85
Transaction and related costs, pre-tax	157
Transaction and related costs, after-tax	$138

Spinoff_of_Health_Care_Busines3

Spinoff of Health Care Business and Related Costs - Results of Operations (Details) (Health Care Spin-off [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Health Care Spin-off [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	$1,320	$1,591	$1,596
Income before income taxes	130	304	310
Provision for income taxes	-80	-101	-109
Net income	$50	$203	$201

Spinoff_of_Health_Care_Busines4

Spinoff of Health Care Business and Related Costs - Assets and Liabilities (Details) (Health Care Spin-off [Member], USD $)	Oct. 31, 2014
In Millions, unless otherwise specified
Health Care Spin-off [Member]
Assets
Cash	$120
Accounts receivable, net	37
Inventories	289
Property, plant and equipment, net	271
Goodwill	1,429
Other intangible assets	114
Other assets	66
Total Assets	2,326
Liabilities
Accrued expenses	127
Debt	636
Deferred income taxes	60
Other liabilities	7
Total Liabilities	830
Net Assets Transferred in the Spin-Off	$1,496

2014_Organization_Restructurin2

2014 Organization Restructuring Narrative (Details) (USD $)	12 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2014
Restructuring Cost and Reserve
Restructuring charges	$434
2014 Organization Restructuring [Member]
Restructuring Cost and Reserve
Expected cash costs as a percentage of total restructuring charges		80.00%
2014 Organization Restructuring [Member] | North America [Member]
Restructuring Cost and Reserve
Restructuring charges			47
2014 Organization Restructuring [Member] | Europe [Member]
Restructuring Cost and Reserve
Restructuring charges			28
2014 Organization Restructuring [Member] | International [Member]
Restructuring Cost and Reserve
Restructuring charges			58
2014 Organization Restructuring [Member] | Before Tax [Member]
Restructuring Cost and Reserve
Restructuring charges			133
2014 Organization Restructuring [Member] | Minimum [Member]
Restructuring Cost and Reserve
Expected restructuring costs		130
Expected workforce reductions (number of employees)		1,100
2014 Organization Restructuring [Member] | Minimum [Member] | Before Tax [Member]
Restructuring Cost and Reserve
Expected restructuring costs		190
2014 Organization Restructuring [Member] | Maximum [Member]
Restructuring Cost and Reserve
Expected restructuring costs		160
Expected workforce reductions (number of employees)		1,300
2014 Organization Restructuring [Member] | Maximum [Member] | Before Tax [Member]
Restructuring Cost and Reserve
Expected restructuring costs		230

2014_Organization_Restructurin3

2014 Organization Restructuring Tables (Details) (USD $)	12 Months Ended			3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$434
Provision for income taxes	856	828	660
2014 Organization Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Provision for income taxes				-38
Net charges				95
2014 Organization Restructuring [Member] | Cost of products sold [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				40
2014 Organization Restructuring [Member] | Marketing, research and general Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$93

European_Strategic_Changes_Nar

European Strategic Changes (Narrative) (Details) (USD $)	12 Months Ended			26 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
European Strategic Changes [Member]
Restructuring Cost and Reserve
Cash payments	$41	$156	$4
European Strategic Changes [Member]
Restructuring Cost and Reserve
Sale or closure of European manufacturing facilities				5

European_Strategic_Changes_Cha

European Strategic Changes - Charges Incurred (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve
Restructuring charges			$434
Provision for income taxes	856	828	660
European Strategic Changes [Member]
Restructuring Cost and Reserve
Restructuring charges	33	81	299
Provision for income taxes	-3	-15	-57
Net charges	30	66	242
European Strategic Changes [Member] | Cost of Sales [Member]
Restructuring Cost and Reserve
Restructuring charges	11	54	250
European Strategic Changes [Member] | Charges for workforce reductions and other exit costs included in marketing, research and general expenses and other (income) and expense, net
Restructuring Cost and Reserve
Restructuring charges	22	27	49
European Strategic Changes [Member] | Asset impairments and other asset-related charges | Cost of Sales [Member]
Restructuring Cost and Reserve
Restructuring charges	2	53	165
European Strategic Changes [Member] | Charges for workforce reductions | Cost of Sales [Member]
Restructuring Cost and Reserve
Restructuring charges	-5	10	77
European Strategic Changes [Member] | Benefit from pension curtailment | Cost of Sales [Member]
Restructuring Cost and Reserve
Restructuring charges	0	-31	0
European Strategic Changes [Member] | Other exit costs | Cost of Sales [Member]
Restructuring Cost and Reserve
Restructuring charges	$14	$22	$8

Pulp_and_Tissue_Narrative_Deta

Pulp and Tissue Narrative (Details) (USD $)	12 Months Ended			23 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
Restructuring Cost and Reserve
Restructuring charges			($434)
Provision for income taxes	856	828	660
Pulp And Tissue Restructuring [Member]
Restructuring Cost and Reserve
Sale or closure of manufacturing facilities around the world	7
Restructuring charges			-135	-550
Restructuring charges after tax				375
Provision for income taxes			-49
Pulp And Tissue Restructuring [Member] | Cost of products sold [Member]
Restructuring Cost and Reserve
Restructuring charges			($135)

Fair_Value_Information_Narrati

Fair Value Information Narrative (Details) (Fair Value, Inputs, Level 2 [Member], Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Company-owned life insurance (COLI)	$58	$55
Derivative assets	54	62
Derivative liabilities	$116	$49

Fair_Value_Information_Fair_Va

Fair Value Information (Fair Value of Financial Instruments) (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Inputs, Level 1 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and cash equivalents	$789	[1]	$1,054	[1]
Time deposits	130	[2]	222	[2]
Fair Value, Inputs, Level 1 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and cash equivalents	789	[1]	1,054	[1]
Time deposits	130	[2]	222	[2]
Fair Value, Inputs, Level 2 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Short-term debt	777	[3]	63	[3]
Long-term debt	6,179	[4]	5,698	[4]
Fair Value, Inputs, Level 2 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Short-term debt	777	[3]	63	[3]
Long-term debt	6,963	[4]	6,721	[4]
Fair Value, Inputs, Level 3 [Member] | Carrying Amount [Member] | Preferred securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Redeemable securities of subsidiaries	72	[5]	578	[5]
Fair Value, Inputs, Level 3 [Member] | Estimated Fair Value [Member] | Preferred securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Redeemable securities of subsidiaries	$72	[5]	$598	[5]
[1]	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
[2]	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
[3]	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
[4]	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
[5]	The redeemable securities of subsidiaries are not traded in active markets. For certain instruments, fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest or dividend payment dates. Additionally, the fair value of the remaining redeemable securities was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Acquisitions_and_Intangible_As2

Acquisitions and Intangible Assets (Changes in the Carrying Amount of Goodwill) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$3,181	$3,337
Acquisitions		9
Currency and other	-124	-165
Spin-off of health care business	1,429
Goodwill, Ending Balance	1,628	3,181
Personal Care [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	684	764
Acquisitions		6
Currency and other	-59	-86
Spin-off of health care business	0
Goodwill, Ending Balance	625	684
Consumer Tissue [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	641	695
Acquisitions		0
Currency and other	-47	-54
Spin-off of health care business	0
Goodwill, Ending Balance	594	641
K-C Professional and Other [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	424	442
Acquisitions		0
Currency and other	-15	-18
Spin-off of health care business	0
Goodwill, Ending Balance	409	424
Health Care [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	1,432	1,436
Acquisitions		3
Currency and other	-3	-7
Spin-off of health care business	1,429
Goodwill, Ending Balance	$0	$1,432

Acquisitions_and_Intangible_As3

Acquisitions and Intangible Assets (Other Intangible Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Indefinite-lived Intangible Assets
Gross Carrying Amount	$230	$546
Accumulated Amortization	121	310
Trademarks [Member]
Indefinite-lived Intangible Assets
Gross Carrying Amount	117	252
Accumulated Amortization	79	163
Patents and developed technologies [Member]
Indefinite-lived Intangible Assets
Gross Carrying Amount	49	201
Accumulated Amortization	9	85
Other [Member]
Indefinite-lived Intangible Assets
Gross Carrying Amount	64	93
Accumulated Amortization	$33	$62

Debt_LongTerm_Debt_Details

Debt (Long-Term Debt) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Total long-term debt	$6,179	$5,698
Less current portion	549	312
Long-term portion	5,630	5,386
Notes and Debentures [Member]
Debt Instrument [Line Items]
Weighted- Average Interest Rate	4.70%
Maturities (start)	1-Jan-15
Maturities (end)	31-Dec-43
Total long-term debt	5,656	5,163
Dealer Remarketable Securities [Member]
Debt Instrument [Line Items]
Weighted- Average Interest Rate	4.30%
Maturities (start)	1-Jan-15
Maturities (end)	31-Dec-16
Total long-term debt	200	200
Industrial Development Revenue Bonds [Member]
Debt Instrument [Line Items]
Weighted- Average Interest Rate	0.20%
Maturities (start)	1-Jan-15
Maturities (end)	31-Dec-34
Total long-term debt	261	261
Bank Loans And Other Financings In Various Currencies [Member]
Debt Instrument [Line Items]
Weighted- Average Interest Rate	5.80%
Maturities (start)	1-Jan-15
Maturities (end)	31-Dec-25
Total long-term debt	$62	$74

Debt_Narrative_Details

Debt (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2006	Dec. 31, 2014	Dec. 31, 2012	Sep. 30, 2013
Debt Instrument [Line Items]
Scheduled maturity of long-term debt in 2015			549,000,000
Scheduled maturity of long-term debt in 2016			607,000,000
Scheduled maturity of long-term debt in 2017			963,000,000
Scheduled maturity of long-term debt in 2018			905,000,000
Scheduled maturity of long-term debt in 2019			311,000,000
Expiring 2019 [Member]
Debt Instrument [Line Items]
Revolving credit facility			2,000,000,000
Expiration date of revolving credit facility	30-Jun-19
Expired 2014 [Member]
Debt Instrument [Line Items]
Revolving credit facility			1,500,000,000
Dealer Remarketable Securities [Member]
Debt Instrument [Line Items]
Face amount of note		200,000,000
Debt maturity date		31-Dec-16
Aggregate principle amount due October 15, 2022 [Member]
Debt Instrument [Line Items]
Debt issuance date			17-Oct-14
Health Care Spin-off [Member]
Debt Instrument [Line Items]
Face amount of note			640,000,000
Floating rate note due May 19, 2016 [Member]
Debt Instrument [Line Items]
Debt issuance date			22-May-14
Face amount of note			300,000,000
Debt maturity date			19-May-16
1.9% Notes due May 22, 2019 [Member]
Debt Instrument [Line Items]
Face amount of note			300,000,000
Debt maturity date			22-May-19
Interest rate of note			1.90%
Floating Rate Notes Due May 15, 2016 [Member]
Debt Instrument [Line Items]
Debt issuance date	31-May-13
Face amount of note	250,000,000
Debt maturity date	15-May-16
2.4% Notes Due June 1, 2023 [Member]
Debt Instrument [Line Items]
Face amount of note	350,000,000
Debt maturity date	1-Jun-23
Interest rate of note	2.40%
3.7% Notes Due June 1, 2043 [Member]
Debt Instrument [Line Items]
Face amount of note					250,000,000
Debt maturity date	1-Jun-43
Interest rate of note	3.70%
5% Notes Due August 15, 2013 [Member]
Debt Instrument [Line Items]
Face amount of note	500,000,000
Debt maturity date	15-Aug-13
Interest rate of note	5.00%
2.4% Notes Due March 21, 2022 [Member]
Debt Instrument [Line Items]
Face amount of note				$300,000,000
Debt maturity date				1-Mar-22
Interest rate of note				2.40%

Redeemable_Preferred_and_Commo1

Redeemable Preferred and Common Securities of Subsidiaries (Narratives) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Redeemable Noncontrolling Interest [Line Items]
Return on redeemable preferred securities and noncontrolling interests and other	$26	$27	$27
Preferred Securities Class A-2 [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption value of preferred securities	$500

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award
Shares of common stock available for grants	22
Stock-based compensation	$52	$92	$67
Deferred income tax benefits on stock-based compensation	19	35	20
Weighted-average fair value of options granted	$7.89	$7.15	$3.25
Excess tax benefits	37	50	50
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Stock options term, years	10 years
Vesting percentage at the end of each of the first two 12 months period	30.00%
Vesting percentage at the end of third 12 months period	40.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	79	138	161
Restricted share units [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Restricted shares vesting period	3 years
Performance-based restricted share units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Performance-based share units vesting range, percentage	0
Performance-based restricted share units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Performance-based share units vesting range, percentage	2
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Total fair value of restricted shares and restricted share units	$102	$45	$101

StockBased_Compensation_Schedu

Stock-Based Compensation (Schedule of Assumptions Used to Estimate Weighted-Average Fair Value of Options Granted) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield	3.50%	3.70%	4.50%
Volatility	13.41%	15.40%	12.86%
Risk-free interest rate	1.73%	0.87%	1.08%
Expected lifebyears	5 years	5 years 1 month 6 days	5 years 9 months 18 days

StockBased_Compensation_Schedu1

Stock-Based Compensation (Schedule of Unrecognized Compensation Costs and Amortization Periods) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Total remaining unrecognized compensation costs, nonvested stock options	$8
Weighted- Average Service Years	1 year
Restricted share units [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Total remaining unrecognized compensation costs, nonvested awards other than options	5
Weighted- Average Service Years	6 months
Performance-based restricted share units [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Total remaining unrecognized compensation costs, nonvested awards other than options	$44
Weighted- Average Service Years	1 year 2 months 12 days

StockBased_Compensation_Schedu2

Stock-Based Compensation (Schedule of Stock-Based Compensation Activity) (Details) (Employee Stock Option [Member], USD $)	12 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at January 1, 2014, shares	7,223
Granted, shares	1,798
Exercised, shares	-1,860
Forfeited or expired, shares	-506
Outstanding at December 31, 2014, shares	6,961
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at January 1, Weighted-Average Exercise Price	$75.77
Granted, Weighted-Average Exercise Price	$112
Exercised, Weighted-Average Exercise Price	$68.02
Forfeited or expired, Weighted-Average Exercise Price	$97.57
Outstanding at December 31, Weighted-Average Exercise Price	$82.32
Exercisable at December 31, 2014, shares	3,846
Exercisable at December 31, Weighted-Average Exercise Price	$68.26
Outstanding at December 31, Weighted-Average Remaining Contractual Term	6 years 6 months 4 days
Exercisable at December 31, Weighted-Average Remaining Contractual Term	4 years 9 months 4 days
Outstanding at December 31, Aggregate Intrinsic Value	$231
Exercisable at December 31, Aggregate Intrinsic Value	$182
Health Care Spin-off [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Conversion for spin-off of health care business, shares	306
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Conversion for spin-off of health care business, Weighted-Average Exercise Price	$82.26

StockBased_Compensation_Schedu3

Stock-Based Compensation (Schedule of Other Stock-Based Awards Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Time-Vested Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at January 1, 2014, shares	257
Granted, shares	73
Vested, shares	-70
Forfeited, shares	-38
Nonvested at December 31, 2014, shares	244
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested at January 1, 2013, Weighted-Average Grant-Date Fair Value	$81.38
Granted, Weighted-Average Grant-Date Fair Value	$100.95
Vested, Weighted-Average Grant-Date Fair Value	$81.97
Forfeited, Weighted-Average Grant-Date Fair Value	$84.01
Nonvested at December 31, 2013, Weighted-Average Grant-Date Fair Value	$86.34
Time-Vested Restricted Share Units [Member] | Health Care Spin-off [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Dividend equivalent for spin-off of health care business, shares	22
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Dividend equivalent for spin-off of health care business, Weighted-Average Grant-Date Fair Value	$78.04
Performance-Based Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at January 1, 2014, shares	2,083
Granted, shares	842
Vested, shares	-894
Forfeited, shares	-301
Nonvested at December 31, 2014, shares	1,809
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested at January 1, 2013, Weighted-Average Grant-Date Fair Value	$79.98
Granted, Weighted-Average Grant-Date Fair Value	$111.77
Vested, Weighted-Average Grant-Date Fair Value	$65.02
Forfeited, Weighted-Average Grant-Date Fair Value	$94.73
Nonvested at December 31, 2013, Weighted-Average Grant-Date Fair Value	$96.35
Performance-Based Restricted Share Units [Member] | Health Care Spin-off [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Dividend equivalent for spin-off of health care business, shares	79
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Dividend equivalent for spin-off of health care business, Weighted-Average Grant-Date Fair Value	$95.80

Employee_Postretirement_Benefi2

Employee Postretirement Benefits (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year		6.30%
Defined Benefit Plan, Health Care Cost Trend Rate Assumed For Fifth Succeeding Fiscal Year		5.10%
Projected benefit obligation (bPBOb)		$6,860	$6,164
Fair value of plan assets		5,914	5,567
Defined Benefit Plan, Significant Concentrations of Risk		there were no significant concentrations of equity or debt securities in any single issuer or industry.
Defined Benefit Pension [Member]
Fair value of plan assets		5,914	5,567	5,375
Weighted-average expected long-term rate or return	5.21%	5.98%	6.26%	6.49%
Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year		100
Defined Benefit Pension [Member] | UNITED STATES
Projected benefit obligation (bPBOb)		4,432	3,866
Fair value of plan assets		3,757	3,565
Principal Plans [Member]
Projected benefit obligation (bPBOb)		6,312	5,640
Fair value of plan assets		5,559	5,205
Weighted-average expected long-term rate or return		5.35%	6.16%	6.43%
Equity Securities [Member]
Defined Benefit Plan, Target Plan Asset Allocations		25.00%
Fixed Income Funds [Member]
Defined Benefit Plan, Target Plan Asset Allocations		75.00%
All Other [Member] | Principal Plans [Member]
Fair value of plan assets		29
Equity Option [Member] | Principal Plans [Member]
Derivative, Notional Amount		950
Treasury Futures [Member] | Principal Plans [Member]
Derivative, Notional Amount		510
Treasury and Equity Futures [Member] | Principal Plans [Member]
Derivative, Notional Amount			$320

Employee_Postretirement_Benefi3

Employee Postretirement Benefits (Summarized Financial Information about Postretirement plans, Excluding Defined Contribution Retirement Plans) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair value of plan assets at end of year	$5,914	$5,567
Noncurrent liabilitybaccrued benefit cost	-1,693	-1,312
Defined Benefit Pension [Member]
Benefit obligation at beginning of year	6,164	6,590
Service cost	46	53	45
Interest cost	279	257	279
Actuarial loss (gain)	986	-422
Currency and other	-207	47
Benefit payments from plans	-356	-343
Direct benefit payments	-10	-13
Currency and other	42	5
Benefit obligation at end of year	6,860	6,164	6,590
Fair value of plan assets at beginning of year	5,567	5,375
Actual return on plan assets	694	268
Employer contributions	185	220
Currency and other	-142	47
Benefit payments	-356	-343
Settlements	-34	0
Fair value of plan assets at end of year	5,914	5,567	5,375
Funded Status	-946	-597
Noncurrent assetbprepaid benefit cost	6	9
Current liabilitybaccrued benefit cost	-13	-12
Noncurrent liabilitybaccrued benefit cost	-939	-594
Net amount recognized	-946	-597
Other Postretirement Benefit Plans, Defined Benefit [Member]
Benefit obligation at beginning of year	761	824
Service cost	13	17
Interest cost	35	32
Actuarial loss (gain)	39	-60
Currency and other	-4	0
Benefit payments from plans	0	0
Direct benefit payments	-56	-52
Currency and other	0	0
Benefit obligation at end of year	788	761
Fair value of plan assets at beginning of year	0	0
Actual return on plan assets	0	0
Employer contributions	0	0
Currency and other	0	0
Benefit payments	0	0
Settlements	0	0
Fair value of plan assets at end of year	0	0
Funded Status	-788	-761
Noncurrent assetbprepaid benefit cost	0	0
Current liabilitybaccrued benefit cost	-51	-56
Noncurrent liabilitybaccrued benefit cost	-737	-705
Net amount recognized	($788)	($761)

Employee_Postretirement_Benefi4

Employee Postretirement Benefits (Principal Plans and All Other Pension Plans) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Projected benefit obligation (bPBOb)	$6,860	$6,164
Accumulated benefit obligation (bABOb)	6,696	5,994
Fair value of plan assets	5,914	5,567
Principal Plans [Member]
Projected benefit obligation (bPBOb)	6,312	5,640
Accumulated benefit obligation (bABOb)	6,221	5,555
Fair value of plan assets	5,559	5,205
All Other Pension Plans [Member]
Projected benefit obligation (bPBOb)	548	524
Accumulated benefit obligation (bABOb)	475	439
Fair value of plan assets	$355	$362

Employee_Postretirement_Benefi5

Employee Postretirement Benefits (Pension Plans with an ABO in Excess of Plan Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
PBO	$6,860	$6,164
ABO	6,696	5,994
Fair value of plan assets	4,111	5,163
ABO in Excess of Plan Assets [Member]
PBO	4,983	5,722
ABO	$4,908	$5,622

Employee_Postretirement_Benefi6

Employee Postretirement Benefits (Components of Net Periodic Benefit Cost) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Defined Benefit Pension [Member]
Service cost	$46		$53		$45
Interest cost	279		257		279
Expected return on plan assets(a)	-332	[1]	-331	[1]	-329	[1]
Recognized net actuarial loss	100		120		111
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Curtailments and Settlements	-20		31		-20
Other	-3		1		-4
Net periodic benefit cost	110		69		122
Other Postretirement Benefit Plans, Defined Benefit [Member]
Service cost	13		17		15
Interest cost	35		32		36
Expected return on plan assets(a)	0		0		0
Recognized net actuarial loss	0		3		1
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Curtailments and Settlements	0		0		0
Other	-1		-2		-1
Net periodic benefit cost	$47		$50		$51
[1]	The expected return on plan assets is determined by multiplying the fair value of plan assets at the remeasurement date, typically the prior year-end adjusted for estimated current year cash benefit payments and contributions, by the expected long-term rate of return.

Employee_Postretirement_Benefi7

Employee Postretirement Benefits (Weighted-Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Pension [Member]
Net cost, Discount rate	3.83%	4.66%	4.04%	4.87%
Net cost, Expected long-term return on plan assets	5.21%	5.98%	6.26%	6.49%
Net cost, Rate of compensation increase	2.63%	2.67%	2.73%	2.91%
Benefit obligations, Discount rate		3.83%	4.66%
Benefit obligations, Rate of compensation increase		2.63%	2.67%
Other Postretirement Benefit Plans, Defined Benefit [Member]
Net cost, Discount rate		4.97%	3.97%	4.70%
Net cost, Expected long-term return on plan assets		0.00%	0.00%	0.00%
Net cost, Rate of compensation increase		0.00%	0.00%	0.00%
Benefit obligations, Discount rate		4.28%	4.97%
Benefit obligations, Rate of compensation increase		0.00%	0.00%

Employee_Postretirement_Benefi8

Employee Postretirement Benefits (Pension Plan Assets of the Principal Plans Measured at fair value) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Projected benefit obligation (bPBOb)	$6,860	$6,164
Accumulated benefit obligation (bABOb)	6,696	5,994
Fair value of plan assets	5,914	5,567
Defined Benefit Pension [Member]
Fair value of plan assets	5,914	5,567	5,375
Principal Plans [Member]
Projected benefit obligation (bPBOb)	6,312	5,640
Accumulated benefit obligation (bABOb)	6,221	5,555
Fair value of plan assets	5,559	5,205
Principal Plans [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	161	146
Principal Plans [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	5,398	5,029
Principal Plans [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0	30
Principal Plans [Member] | U.S. Equity [Member]
Fair value of plan assets	18
Principal Plans [Member] | U.S. Equity [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	4	4
Principal Plans [Member] | U.S. Equity [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	18
Principal Plans [Member] | U.S. Equity [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	4	4
Principal Plans [Member] | U.S. Equity [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	0
Principal Plans [Member] | U.S. Equity [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. Equity [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0
Principal Plans [Member] | U.S. Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Non-U.S. Equity [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	106	123
Principal Plans [Member] | Non-U.S. Equity [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1	1
Principal Plans [Member] | Non-U.S. Equity [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	105	122
Principal Plans [Member] | Non-U.S. Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | International Bonds [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1,438	1,089
Principal Plans [Member] | International Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | International Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1,438	1,089
Principal Plans [Member] | International Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. securitized fixed income [Member]
Fair value of plan assets	6	8
Principal Plans [Member] | U.S. securitized fixed income [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. securitized fixed income [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	6	8
Principal Plans [Member] | U.S. securitized fixed income [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets	28	33
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	175	173
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	28	33
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	9	34
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	166	139
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. government and municipals [Member]
Fair value of plan assets	252	211
Principal Plans [Member] | U.S. government and municipals [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	71	71
Principal Plans [Member] | U.S. government and municipals [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	181	140
Principal Plans [Member] | U.S. government and municipals [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. corporate debt [Member]
Fair value of plan assets	2,167	1,654
Principal Plans [Member] | U.S. corporate debt [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	149	186
Principal Plans [Member] | U.S. corporate debt [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. corporate debt [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. corporate debt [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	2,167	1,654
Principal Plans [Member] | U.S. corporate debt [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	149	186
Principal Plans [Member] | U.S. corporate debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | U.S. corporate debt [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Multi-sector [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1	2
Principal Plans [Member] | Multi-sector [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1	2
Principal Plans [Member] | Multi-sector [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Multi-sector [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Global equity [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1,186	1,691
Principal Plans [Member] | Global equity [Member] | Fair Value, Inputs, Level 1 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | Global equity [Member] | Fair Value, Inputs, Level 2 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	1,186	1,691
Principal Plans [Member] | Global equity [Member] | Fair Value, Inputs, Level 3 [Member] | Mutual and Pooled Funds [Member]
Fair value of plan assets	0	0
Principal Plans [Member] | All Other [Member]
Fair value of plan assets	29
Principal Plans [Member] | All Other [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	29
Principal Plans [Member] | Insurance Contract [Member]
Fair value of plan assets		30
Principal Plans [Member] | Insurance Contract [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	0
Principal Plans [Member] | Insurance Contract [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	0	30
Principal Plans [Member] | Equity - Held Through Mutual and Pooled Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets		0
Principal Plans [Member] | Equity - Held Through Mutual and Pooled Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets		0
U.S. Equity [Member] | Equity - Assets Held Directly [Member]
Fair value of plan assets		1
U.S. Equity [Member] | Equity - Assets Held Directly [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets		1
U.S. Equity [Member] | Equity - Assets Held Directly [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets		0
U.S. Equity [Member] | Equity - Assets Held Directly [Member] | Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets		$0

Employee_Postretirement_Benefi9

Employee Postretirement Benefits (Cash Contributions to its Pension Trusts) (Details) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Defined Benefit Pension [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One	$430
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	432
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	438
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	440
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	439
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	2,181
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One	52
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	53
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	55
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	57
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	58
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	$309

Recovered_Sheet1

Employee Postretirement Benefits (Defined Contribution Pension Plans) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Costs charged to expense for defined contribution pension plans	$121	$117	$108
UNITED STATES
Costs charged to expense for defined contribution pension plans	87	90	82
Outside the United States [Member]
Costs charged to expense for defined contribution pension plans	$34	$27	$26

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Change in Components of Accumulated Other Comprehensive Income Attributable to Kimberly-Clark (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Accumulated Other Comprehensive Income, Beginning Balance	($2,242)
Net current period other comprehensive income (loss)	-1,090		-175		-178
Spin-off of health care business	9		0		0
Accumulated Other Comprehensive Income, Ending Balance	-3,312		-2,242
Unrealized Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Accumulated Other Comprehensive Income, Beginning Balance	-525		-26
Other comprehensive income (loss) before reclassifications	-819		-499
(Income) loss reclassified from AOCI	0		0
Net current period other comprehensive income (loss)	-819		-499
Spin-off of health care business	9
Accumulated Other Comprehensive Income, Ending Balance	-1,335		-525
Defined Benefit Plans [Member] | Defined Benefit Pension Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Accumulated Other Comprehensive Income, Beginning Balance	-1,668		-1,928
Other comprehensive income (loss) before reclassifications	-313		218
(Income) loss reclassified from AOCI	57	[1]	42	[1]
Net current period other comprehensive income (loss)	-256		260
Spin-off of health care business	0
Accumulated Other Comprehensive Income, Ending Balance	-1,924		-1,668
Defined Benefit Plans [Member] | Other Postretirement Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Accumulated Other Comprehensive Income, Beginning Balance	-15		-53
Other comprehensive income (loss) before reclassifications	-23		36
(Income) loss reclassified from AOCI	1	[1]	2	[1]
Net current period other comprehensive income (loss)	-22		38
Spin-off of health care business	0
Accumulated Other Comprehensive Income, Ending Balance	-37		-15
Cash Flow Hedges and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Accumulated Other Comprehensive Income, Beginning Balance	-34		-52
Other comprehensive income (loss) before reclassifications	29		24
(Income) loss reclassified from AOCI	-11		-6
Net current period other comprehensive income (loss)	18		18
Spin-off of health care business	0
Accumulated Other Comprehensive Income, Ending Balance	($16)		($34)
[1]	Included in computation of net periodic pension and postretirement benefits costs (see Note 11)

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Narratives) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Equity [Abstract]
Unrecognized net actuarial loss	$2,016
Unrecognized net prior service credit	54
Defined Benefit Plan, Amortization of Net Gains (Losses)	116
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	($10)

Accumulated_Other_Comprehensiv4

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Components of Stockholders' Equity) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized translation	($835)	($494)	$215
Employee postretirement benefits	-275	302	-377
Recognition of effective portion of hedges	18	37	-20
Amortization included in net income	-5	-10	0
Cash flow hedges and other, before Tax	15	31	-21
Cash flow hedges and other, tax effect	3	-13	5
Cash flow hedges and other, net of tax	18	18	-16
Spin-off of health care business	9	0	0
Change in AOCI	-1,070	-183	-193
Defined Benefit Pension Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Defined benefit and other postretirement benefit plans, tax effect	167	-176	165
Employee postretirement benefits	-256	260	-350
Other Postretirement Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Defined benefit and other postretirement benefit plans, tax effect	14	-24	12
Employee postretirement benefits	-22	38	-22
Attributable to Kimberly-Clark [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized translation, before tax	-826	-495	204
Unrealized translation, tax effect	7	-4	-9
Unrealized translation	-819	-499	195
Unrecognized net actuarial loss and transition amount [Member] | Defined Benefit Pension Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Funded status recognition	624	-356	588
Amortization included in net periodic benefit cost	100	120	90
Currency and other	-69	8	20
Other comprehensive income (loss), before tax	-455	468	-518
Unrecognized net actuarial loss and transition amount [Member] | Other Postretirement Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss), before tax	-36	65	-32
Unrecognized prior service cost [Member] | Defined Benefit Pension Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Currency and other	3	1	-3
Other comprehensive income (loss), before tax	32	-32	3
Funded status recognition	42	0	0
Amortization included in net periodic benefit cost	-7	-31	0
Unrecognized prior service cost [Member] | Other Postretirement Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss), before tax	0	-3	-2
Cash Flow Hedges and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Currency and other	-2	-4	1
Spin-off of health care business	$0

Leases_and_Commitments_Future_

Leases and Commitments (Future Minimum Obligations under Operating Leases) (Details) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Leases and Commitments [Line Items]
2015	$151
2016	117
2017	94
2018	70
2019	56
Thereafter	99
Future minimum obligations	$587

Leases_and_Commitments_Narrati

Leases and Commitments (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Leases and Commitments
Consolidated rental expense	$303	$316	$303
2015	297
2016	187
2017	165
2018	141
2019	147
Beyond 2019	$163

Objectives_and_Strategies_for_2

Objectives and Strategies for Using Derivatives (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Assets	$54	$62
Liabilities	116	49
Fair value hedge ineffectiveness is immaterial assertion	Fair value hedges resulted in no significant ineffectiveness in each of the three years ended DecemberB 31, 2014
Gain from hedged firm commitment not qualifying as fair value hedge	0
Cash flow hedge ineffectiveness is immaterial assertion	Cash flow hedges resulted in no significant ineffectiveness in each of the three years ended DecemberB 31, 2014
Gains or losses reclassified into earnings resulting from discontinuance of cash flow hedges	0
Losses on undesignated foreign exchange hedging instruments recognized in other (income) and expense	192	74	-69
Fair Value Hedging [Member]
Aggregate notional value	250
Cash Flow Hedging [Member]
Maximum maturity of cash flow hedges	1-Dec-17
Not Designated as Hedging Instrument [Member]
Aggregate notional value	2,600
Foreign Exchange Contract [Member]
Assets	54	34
Liabilities	102	49
Foreign Exchange Contract [Member] | Cash Flow Hedging [Member]
Aggregate notional value	820
Interest Rate Contract [Member]
Assets	0	22
Liabilities	4	0
Interest Rate Contract [Member] | Cash Flow Hedging [Member]
Aggregate notional value	200
Commodity Contract [Member]
Assets	0	6
Liabilities	$10	$0

Income_Taxes_Analysis_of_the_P

Income Taxes (Analysis of the Provision for Income Taxes) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
United States	$350	$292	$112
State	48	99	15
Other countries	387	286	289
Total	785	677	416
United States	67	85	218
State	-16	14	36
Other countries	20	52	-10
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	71	151	244
Total provision for income taxes	$856	$828	$660

Income_Taxes_Income_before_Inc

Income Taxes (Income before Income Taxes) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
United States	$1,571	$1,557	$1,223
Other countries	684	1,084	887
Income From Continuing Operations Before Income Taxes and Equity Interests	$2,255	$2,641	$2,110

Income_Taxes_Deferred_Income_T

Income Taxes (Deferred Income Tax Assets (Liabilities)) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]
Pension and other postretirement benefits	$883	$728
Tax credits and loss carryforwards	538	604
Deferred Tax Assets, Property, Plant and Equipment	77	104
Other	590	516
Deferred Tax Assets, Gross	2,088	1,952
Deferred Tax Assets, Valuation Allowance	-215	-197
Deferred Tax Assets, Net	1,873	1,755
Deferred Tax Liability Noncurrent Pension Postretirement And Other Employee Benefits	-260	-259
Deferred Tax Liabilities, Property, Plant and Equipment	-1,162	-1,244
Deferred Tax Liabilities, Undistributed Foreign Earnings	-223	-205
Deferred Tax Liabilities, Other	-339	-396
Deferred Tax Liabilities, Gross	-1,984	-2,104
Deferred Tax Liabilities, Net	($111)	($349)

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Valuation Allowance
Income tax loss carryforwards	$1,000,000,000
Income tax loss carryforwards expire amount	445,000,000
Income tax loss carryforwards expiration dates	2015 through 2034
Remaining amount of loss carryforwards that has no expiration date	557,000,000
Unremitted earnings	8,600,000,000
Unrecognized tax benefits	266,000,000
Total accrued penalties and net accrued interest	28,000,000	42,000,000
Aggregate resolution of uncertainties	$130,000,000
Year federal income tax returns have been audited	2011
Administrative appeals or litigation	1999 to 2011
State and Local Jurisdiction [Member]
Valuation Allowance
Statute for potential adjustments, period	3 to 5 years
Pending refund actions, period	two

Income_Taxes_Reconciliation_of

Income Taxes (Reconciliation of Income Tax Provision) (Details)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Abstract]
Tax at U.S. statutory rate applied to income before income taxes	35.00%		35.00%		35.00%
State income taxes, net of federal tax benefit	0.70%		2.70%		1.60%
Statutory rates other than U.S. statutory rate	-3.00%		-3.00%		-2.80%
Venezuela balance sheet remeasurement and inflationary impact	4.90%		-0.80%		-0.40%
Other-net	0.40%	[1]	-2.50%	[1]	-2.10%	[1]
Effective income tax rate	38.00%		31.40%		31.30%
[1]	Other - net is composed of numerous items, none of which is greater than 1.75 percent of income before income taxes.

Income_Taxes_Unrecognized_Inco

Income Taxes (Unrecognized Income Tax Benefits) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at January 1	$473	$435	$558
Gross increases for tax positions of prior years	36	73	30
Gross decreases for tax positions of prior years	-91	-31	-104
Gross increases for tax positions of the current year	87	37	52
Settlements	-77	-35	-100
Unrecognized Tax Benefits, Other	12	6	1
Balance at December 31	$416	$473	$435

Income_Taxes_Remaining_Tax_Yea

Income Taxes (Remaining Tax Years Subject to Examination) (Details)	12 Months Ended
	Dec. 31, 2014
Minimum [Member] | United States
Income Tax Examination [Line Items]
Tax years subject to examination	2012
Minimum [Member] | United Kingdom
Income Tax Examination [Line Items]
Tax years subject to examination	2012
Minimum [Member] | Brazil
Income Tax Examination [Line Items]
Tax years subject to examination	2009
Minimum [Member] | Korea
Income Tax Examination [Line Items]
Tax years subject to examination	2014
Minimum [Member] | China
Income Tax Examination [Line Items]
Tax years subject to examination	2003
Maximum [Member] | United States
Income Tax Examination [Line Items]
Tax years subject to examination	2014
Maximum [Member] | United Kingdom
Income Tax Examination [Line Items]
Tax years subject to examination	2014
Maximum [Member] | Brazil
Income Tax Examination [Line Items]
Tax years subject to examination	2014
Maximum [Member] | China
Income Tax Examination [Line Items]
Tax years subject to examination	2014

Earnings_Per_Share_Average_Com

Earnings Per Share (Average Common shares Outstanding Basic and Diluted) (Details)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Basic	374.5	384	393
Dilutive effect of stock options and restricted share unit awards	2.9	3.3	3.1
Diluted	377.4	387.3	396.1

Earnings_Per_Share_Options_Out

Earnings Per Share (Options Outstanding not Included in Computation of Diluted EPS) (Details) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Average number of share equivalents (millions)	1.1	1.1	1.1
Weighted-average exercise price	$107.54	$103.29	$78.54
Options outstanding at year-end (millions)	1.7	1.8	1.7

Earnings_Per_Share_Narratives_

Earnings Per Share (Narratives) (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Earnings Per Share [Abstract]
Common shares outstanding	365.3	380.8	389.3

Business_Segment_and_Geographi1

Business Segment and Geographic Data Information (Narrative) (Details) (USD $)	12 Months Ended					3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2014
Restructuring charges				$434
Charge for Venezuelan balance sheet remeasurement	-462	-36		0
Other Operating Income (Expense), Net	-453	-7	[1]	5	[1]
Net Sales Percentage to One Customer [Member] | Wal-Mart Stores, Inc. [Member]
Net sales to Wal-Mart Stores, percent	13.00%	13.00%		13.00%
K-C Venezuela [Member]
Charge for Venezuelan balance sheet remeasurement	462
Dispute in Middle East [Member]
Other Operating Income (Expense), Net	35
K-C Venezuela [Member]
Charge for Venezuelan balance sheet remeasurement	41
Other Income [Member] | K-C Venezuela [Member]
Charge for Venezuelan balance sheet remeasurement	421	36
Before Tax [Member] | 2014 Organization Restructuring [Member]
Restructuring charges						$133
[1]	Segment operating profit excludes other (income) and expense, net and income and expenses not associated with the business segments.

Business_Segment_and_Geographi2

Business Segment and Geographic Data Information (Information Concerning Consolidated Operations by Business Segment) (Details) (USD $)	12 Months Ended						23 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2012
Net Sales	$19,724	[1]	$19,561	[1]	$19,467	[1]
Operating Profit	2,521	[2]	2,903	[2]	2,377	[2]
Charges for workforce reductions and other exit costs					434
Depreciation and Amortization	862		863		857
Assets	15,526		18,919		19,873		19,873
Capital Spending	1,039		953		1,093
United States
Net Sales	8,573		8,557		8,514
Personal Care [Member]
Net Sales	9,635	[1]	9,536	[1]	9,576	[1]
Operating Profit	1,803	[2]	1,698	[2]	1,660	[2]
Charges for workforce reductions and other exit costs					213
Depreciation and Amortization	359		332		315
Assets	6,373		6,623		7,014		7,014
Capital Spending	501		461		551
Consumer Tissue [Member]
Net Sales	6,645	[1]	6,637	[1]	6,527	[1]
Operating Profit	1,062	[2]	988	[2]	887	[2]
Charges for workforce reductions and other exit costs					191
Depreciation and Amortization	299		318		331
Assets	5,229		5,483		5,531		5,531
Capital Spending	314		328		352
K-C Professional and Other [Member]
Net Sales	3,388	[1]	3,323	[1]	3,283	[1]
Operating Profit	604	[2]	605	[2]	542	[2]
Charges for workforce reductions and other exit costs					29
Depreciation and Amortization	132		138		141
Assets	2,339		2,431		2,739		2,739
Capital Spending	143		118		116
Health Care [Member]
Depreciation and Amortization	69		71		59
Assets	0		2,370		2,531		2,531
Capital Spending	75		44		42
Corporate and Other [Member]
Net Sales	56	[1]	65	[1]	81	[1]
Operating Profit	-495	[2],[3]	-381	[2],[3]	-717	[2],[3]
Depreciation and Amortization	3		4		11
Assets	1,585		2,012		2,058		2,058
Capital Spending	6		2		32
Ongoing Operations [Member]
Depreciation and Amortization	793		792		798
Assets	15,526		16,549		17,342		17,342
Capital Spending	964		909		1,051
Other (Income) And Expense, Net [Member]
Charges for workforce reductions and other exit costs					1
European Strategic Changes [Member]
Charges for workforce reductions and other exit costs	33		81		299
European Strategic Changes [Member] | Personal Care [Member]
Charges for workforce reductions and other exit costs	20		36		213
European Strategic Changes [Member] | Consumer Tissue [Member]
Charges for workforce reductions and other exit costs	12		27		66
European Strategic Changes [Member] | K-C Professional and Other [Member]
Charges for workforce reductions and other exit costs	1		13		20
European Strategic Changes [Member] | Other (Income) And Expense, Net [Member]
Charges for workforce reductions and other exit costs	0		5		0
Pulp And Tissue Restructuring [Member]
Charges for workforce reductions and other exit costs					135		550
Pulp And Tissue Restructuring [Member] | Personal Care [Member]
Charges for workforce reductions and other exit costs					0
Pulp And Tissue Restructuring [Member] | Consumer Tissue [Member]
Charges for workforce reductions and other exit costs					125
Pulp And Tissue Restructuring [Member] | K-C Professional and Other [Member]
Charges for workforce reductions and other exit costs					9
Pulp And Tissue Restructuring [Member] | Other (Income) And Expense, Net [Member]
Charges for workforce reductions and other exit costs					$1
[1]	Net sales in the United States to third parties totaled $8,573, $8,557 and $8,514 in 2014, 2013 and 2012, respectively.
[2]	Segment operating profit excludes other (income) and expense, net and income and expenses not associated with the business segments.
[3]	Corporate & Other and other (income) and expense, net include the following charges:

Business_Segment_and_Geographi3

Business Segment and Geographic Data Information (Sales of Principal Products) (Details) (USD $)	12 Months Ended
In Billions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Sales of Principal Products	$19.70	$19.60	$19.50
Consumer Tissue Products [Member]
Sales of Principal Products	6.6	6.6	6.5
Baby and Child Care Products [Member]
Sales of Principal Products	7	7	7.1
Away from Home Professional Products [Member]
Sales of Principal Products	3.4	3.3	3.3
All Other [Member]
Sales of Principal Products	$2.70	$2.70	$2.60

Supplemental_Data_Supplemental

Supplemental Data (Supplemental Income Statement Data) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Data
Advertising expense	$767	$769	$804
Research expense	$368	$333	$335

Supplemental_Data_Supplemental1

Supplemental Data Supplemental Data (Equity Method Investment Data) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Sales	$2,452	$2,638	$2,514
Gross Profit	781	950	864
Operating Profit	485	642	567
Net Income	304	426	368
Corporation's Share of Net Income	146	205	177
Current Assets	1,016	1,197	1,054
Non- Current Assets	1,040	1,124	1,068
Current Liabilities	690	847	712
Non- Current Liabilities	963	845	837
Stockholders' Equity	$403	$629	$573

Supplemental_Data_Narrative_De

Supplemental Data (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]
Investments in Equity Companies	$257,000,000	$382,000,000
Retained Earnings, Undistributed Earnings from Equity Method Investees	1,000,000,000
Property, Plant and Equipment, Net	7,359,000,000	7,948,000,000
United States
Schedule of Equity Method Investments [Line Items]
Property, Plant and Equipment, Net	3,685,000,000	3,917,000,000
Kimberly-Clark de Mexico, S.A.B. de C.V. and subsidiaries [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	47.90%
Investments in Equity Companies	194,000,000
Equity Method Investments, Fair Value Disclosure	$3,400,000,000

Supplemental_Data_Summary_of_A

Supplemental Data (Summary of Accounts Receivable, Net) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Supplemental Data (Millions of dollars) [Abstract]
From customers	$2,079	$2,345
Other	210	271
Less allowance for doubtful accounts and sales discounts	-66	-71
Total	$2,223	$2,545

Supplemental_Data_Summary_of_I

Supplemental Data (Summary of Inventories) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory [Line Items]
Raw materials	$426	$462
Work in process	215	286
Finished goods	1,183	1,401
Supplies and other	288	326
Gross inventories	2,112	2,475
Excess of FIFO or weighted-average cost over LIFO cost	-220	-242
Total	1,892	2,233
LIFO
Inventory [Line Items]
Raw materials	104	143
Work in process	120	189
Finished goods	511	648
Supplies and other	0	0
Gross inventories	735	980
Excess of FIFO or weighted-average cost over LIFO cost	-220	-242
Total	515	738
Non- LIFO
Inventory [Line Items]
Raw materials	322	319
Work in process	95	97
Finished goods	672	753
Supplies and other	288	326
Gross inventories	1,377	1,495
Excess of FIFO or weighted-average cost over LIFO cost	0	0
Total	$1,377	$1,495

Supplemental_Data_Summary_of_P

Supplemental Data (Summary of Property, Plant and Equipment, Net) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Supplemental Data
Land	$177	$196
Buildings	2,574	2,776
Machinery and equipment	13,437	14,193
Construction in progress	591	515
Total before accumulated depreciation	16,779	17,680
Less accumulated depreciation	-9,420	-9,732
Total	$7,359	$7,948

Supplemental_Data_Summary_of_A1

Supplemental Data (Summary of Accrued Expenses) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Supplemental Data
Accrued advertising and promotion	$326	$355
Accrued salaries and wages	415	471
Accrued rebates	258	358
Accrued taxes - income and other	330	336
Derivative Liability, Current	113	44
Other	532	496
Total	$1,974	$2,060

Supplemental_Data_Summary_of_C

Supplemental Data (Summary of Cash Flow Effects of Decrease (Increase) in Operating Working Capital) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts receivable	$267	$4	($38)
Inventories	12	100	9
Trade accounts payable	-30	128	45
Accrued expenses	-120	-177	133
Accrued income taxes	-159	-90	13
Derivatives	103	5	-86
Currency and other	-249	-128	43
Total	($176)	($158)	$119

Supplemental_Data_Other_Cash_F

Supplemental Data (Other Cash Flow Data and Interest Expense) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Data
Interest paid	$300	$307	$299
Income taxes paid	$926	$776	$451

Valuation_and_Qualifying_Accou2

Valuation and Qualifying Accounts (Schedule of Valuation and Qualifying Accounts) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$51		$60		$57
Charged to Costs and Expenses	13		0		9
Charged to Other Accounts	-7	[1]	-4	[1]	0	[1]
Deductions	7	[2]	5	[2]	6	[2]
Balance at End of Period	50		51		60
Allowances for Sales Discounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	20		20		21
Charged to Costs and Expenses	265		275		280
Charged to Other Accounts	-1	[1]	-1	[1]	0	[1]
Deductions	268	[3]	274	[3]	281	[3]
Balance at End of Period	16		20		20
Deferred Taxes [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	197		215		229
Charged to Costs and Expenses	30		-11		-18
Charged to Other Accounts	0		0		0
Deductions	12	[4]	7	[4]	-4	[4]
Balance at End of Period	$215		$197		$215
[1]	Includes bad debt recoveries and the effects of changes in foreign currency exchange rates.
[2]	Primarily uncollectible receivables written off.
[3]	Sales discounts allowed.
[4]	Represents the net currency effects of translating valuation allowances at current rates of exchange.